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ZUSAMMENFASSUNG 
 
Zusammenfassung 
 
Die korrekte Faltung und Sortierung ist sehr wichtig für Proteine um ihren Zielort zu 
erreichen und die physiologische Funktion auszuüben. Entlang des sekretorischen Weges 
spielen mehrere Faktoren eine Rolle um dieses in der Zelle umzusetzen. Zum einen ist die 
Glykosylierung von Proteinen an der Zielfindung beteiligt. Um die Glykoproteine richtig 
sortieren zu können bedarf es spezieller Proteine, die Zuckerstrukturen erkennen können und 
diese binden. Intrazelluläre Lektine bewerkstelligen dies und sind dabei in die Sortierung, 
dem Transport und der Qualitätskontrolle von neu synthetisierten Glykoproteinen involviert. 
Darüber hinaus wurde in den letzten Jahren die Bedeutung von speziellen Membran-
Mikrodomänen (Lipid rafts oder Detergenz Resistente Membranen (DRMs)) entdeckt. Die 
Assoziation mit diesen Mikrodomänen ist ebenfalls ein wichtiger Faktor für die Sortierung 
und Funktion von vielen Proteinen. Wenn Proteine aufgrund von Defekten in der 
Sortierungsmaschinerie falsch sortiert werden, kann sich dies in verschiedenen Krankheiten 
äußern. Fortschritte in der Aufklärung von neu charakterisierten Lektinen, sowie deren 
Zusammenspiel mit anderen Lektinen und Glykoproteinen entlang des sekretorischen Weges 
in speziellen Membran-Mikrodomänen, erweitern unser Verständnis über die 
Sortierungsmaschinerie und können Aufschluss über Pathomechanismen in diesem Bereich 
der Zelle geben. 
Ziel dieser Studie war die Charakterisierung des Proteins Vesicular integral-membrane 
protein (VIP36) und deren Rolle in der Sortierung und dem Transport von Glykoproteinen. 
VIP36 ist ein intrazelluläres Lektin welches 1994 erstmals aus CHAPS DRMs isoliert wurde. 
Dieses Protein wurde in verschiedenen zellulären Kompartimenten, wie dem 
Endoplasmatischen Retikulum (ER), ER-Golgi Intermediär Kompartiment (ERGIC) und 
Golgi-Apparat gefunden. Auch ein Erreichen der Zellmembran konnte in einigen Studien 
gezeigt werden. VIP36 bindet hauptsächlich Glykoproteine, die in ihrer mannosereichen Form 
vorliegen, und wird als Lektin in Sortierungsprozessen und der Qualitätskontrolle nach dem 
ER vermutet. In dieser Arbeit wurden neue Interaktionspartner von VIP36 gesucht und die 
Bindungseigenschaften sowie die zelluläre Lokalisation untersucht. 
Mit dem Einsatz von konfokaler Lasermikroskopie und Immunopräzipitations-Experimenten 
war es mir möglich die beiden Raft-assoziierten Glykoproteine Dipeptidylpeptidase IV 
(DPPIV) und Saccharase-Isomaltase (SI) als neue Interaktionspartner von VIP36 zu 
identifizieren. Keine Interaktion konnte mit den Proteinen Aminopeptidase N (APN) und 
Laktase-Phlorizin Hydrolase (LPH) gefunden werden, welche ebenfalls Glykoproteine sind 
ZUSAMMENFASSUNG 
 
aber keine Assoziation mit Rafts in späteren zellulären Kompartimenten aufweisen. Die 
Interaktion von VIP36 mit DPPIV und SI ist abhängig von deren Glykosylierung, da 
Glykosylierungsinhibitoren die Bindung von VIP36 schwächen. Dies spricht für die Rolle als 
Beförderungsgut der beiden Proteine von VIP36. Darüber hinaus konnte ich in Pulse-Chase 
Experimenten zeigen, dass VIP36 sowohl mannosereich glykosylierte als auch komplex 
glykosylierte Proteinformen von DPPIV und SI bindet und somit im ER und im Golgi-
Apparat aktiv ist. Die Verbindung von VIP36 und den beförderten Proteinen löst sich im 
Trans-Golgi-Netzwerk, da keine Interaktion an der Zelloberfläche beobachtet werden konnte. 
Somit konnte gezeigt werden, dass VIP36 an Sortierungsereignissen in frühen 
Kompartimenten wie dem ER und ERGIC, sowie später entlang des sekretorischen Weges 
(Golgi-Apparat, Trans-Golgi-Netzwerk) eine Rolle spielt. 
Mit der Isolierung von verschiedenen DRMs konnte gezeigt werden, dass VIP36 mit Tween 
20 DRMs assoziiert ist. Diese DRMs stellen frühe Sortierungsplattformen für apikale Proteine 
wie DPPIV und SI dar, in der VIP36 als Sortierungsrezeptor involviert sein könnte. Eine 
Assoziation mit DRMs, die in Membranen des Golgi-Apparates vorherrschen, konnte nicht 
beobachtet werden. Diese Verteilung änderte sich allerdings, wenn die Glykosylierung im 
Golgi-Apparat gehemmt wurde. Unter diesen Bedingungen wird VIP36 in Lubrol WX DRMs 
rekrutiert. Dies könnte aufgrund der Bindung zu DPPIV erfolgen, welches von VIP36 zurück 
in frühere Kompartimente entlang des sekretorischen Weges transportiert werden könnte, um 
eine korrekte Glykosylierung zu erreichen. Dies macht VIP36 zu einem potenziellen 
Kandidaten für die Post-ER Qualitätskontrolle. 
Zusammenfassend konnten die Daten zeigen, dass VIP36 ein multifunktionales Lektin ist, 
welches eine Rolle in der Sortierung von Glykoproteinen sowie der Post-ER 
Qualitätskontrolle spielt. 
 
Schlagwörter: Vesicular intergal-membrane protein (VIP36), intrazelluläre Lektine, 
sekretorischer Weg, Glykoproteintransport, Detergenz Resistente Membranen (DRMs) 
 
ABSTRACT 
 
Abstract 
 
Proteins need to be correctly folded and transported to their targets in the cell to fulfil their 
physiological functions. Along the secretory pathway there are different processes which are 
involved in the sorting machinery. One important feature for reaching the final destination is 
the glycosylation of proteins. For the recognition of glycoproteins special proteins exist, 
namely intracellular lectins, which are involved in sorting, trafficking and quality control of 
newly synthesized glycoproteins. Another feature which became important in the last years is 
the association with special membrane microdomains called lipid rafts or detergent resistant 
membranes (DRMs). Association with lipid rafts was shown to be crucial for the right sorting 
and function of many proteins. Different diseases can be caused by missorted proteins which 
are based on defects in the sorting machinery.  
The aim of this study was the characterization of the biochemical role of vesicular integral-
membrane protein (VIP36) in glycoprotein trafficking and sorting. VIP36 is an intracellular 
lectin which was first isolated from CHAPS DRMs in 1994. It was found to be localized in 
different cellular compartments (e.g. endoplasmic reticulum (ER), ER-Golgi intermediate 
compartment (ERGIC), and Golgi-apparatus) and at the cell surface, binding mainly to high-
mannose glycosylated proteins. Furthermore it is proposed to play a role in sorting events and 
post-ER quality control. In this study, I was searching for new interaction partners of VIP36 
and investigated binding properties as well as cellular localization of this particular protein.  
By using confocal laser microscopy and immunoprecipitation experiments, I was able to 
identify the two raft-associated glycoproteins dipeptidyl peptidase IV (DPPIV) and sucrase-
isomaltase (SI) as interaction partners for VIP36. No interaction with the proteins 
aminopeptidase N (APN) and lactase-phlorizin hydrolase (LPH), which are not associated 
with DRMs of later cellular compartments, could be observed. The interaction of VIP36 with 
DPPIV and SI was found to be glycosylation-dependent since treatment with glycosylation-
inhibitors impairs the binding of VIP36. This makes these proteins potential cargo for this 
lectin. Moreover, it could be shown that VIP36 binds to its cargo in early as well as in late 
compartments along the secretory pathway, which was obtained by pulse chase experiments 
showing an association of VIP36 with SI and DPPIV, when mannose-rich and complex 
glycosylated. VIP36 and its cargo separate at the stage of the trans-Golgi network (TGN) 
since no association could be observed when the two glycoproteins were supposed to reach 
the cell surface. Therefore, VIP36 might play a role in sorting events in early compartments 
(e.g. ER, ERGIC) and also later along the secretory pathway (e.g. Golgi-apparatus, TGN).  
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DRM extraction experiments revealed an association of VIP36 with Tween 20 DRMs, which 
are proposed to play a role in early polarized sorting. This indicates an involvement of VIP36 
in early polarized sorting of DPPIV and SI. No association with DRMs of Golgi membranes 
could be observed. However, when glycosylation in the Golgi was inhibited VIP36 was 
recruited in Lubrol WX DRMs possibly because of binding to DPPIV, relocating it back to 
earlier compartments for an additional round of glycosylation. This makes VIP36 a promising 
candidate for post-ER quality control. 
Taken together, VIP36 is a multifunctional intracellular lectin which plays a role in sorting of 
glycoproteins along the secretory pathway and possibly in post-ER quality control. 
 
Keywords: Vesicular integral-membrane protein (VIP36), intracellular lectins, secretory 
pathway, transport of glycoproteins, detergent resistant membranes (DRMs) 
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1. Introduction 
 
Proteins need to be correctly sorted and transported to their targets in the cell to fulfil their 
physiological functions. Several diseases are caused by the missorting or malfunction of 
proteins including the gastrointestinal tract disorders congenital sucrase-isomaltase 
deficiency, cystic fibrosis, glucose-galactose malabsorbtion, and congenital lactase deficiency 
(Naim et al. 1988a, Riordan et al. 1989, Turk et al. 1991, Kuokkanen et al. 2006). 
Along the secretory pathway there are many different processes which play a role for protein 
trafficking and sorting. One important feature is the glycosylation of proteins. The 
glycosylation process is present in the cytosol, the endoplasmic reticulum (ER) and the Golgi 
apparatus (Golgi). It plays a crucial role as a sorting signal and is required for the proper 
folding of glycoproteins. Defects in glycosylation of a certain protein can cause missorting, 
loss of function and could be associated with the pathogenesis of different diseases.  
During the glycosylation process, proteins are transported and controlled by other proteins. 
Several of these events are exerted by intracellular lectins, such as calnexin (CNX), 
calreticulin (CRT), and mannose-6-phosphate receptors. It is known that these lectins are 
essential for the quality control and exit of the ER or transport to other cellular compartments 
(e.g. lysosomes). When lectins are not able to bind certain glycoproteins, this can also cause 
diseases like bleeding disorder (Nichols et al. 1998) or even embryonic or perinatal lethality, 
as was shown for the absence of CNX or CRT in mice (reviewed in Anelli & Sitia 2008). 
Another feature which becomes important in the last three decades is the association of 
proteins with lipid rafts or detergent resistant membranes (DRMs) in biological membranes. 
Many proteins need this association for finding interaction partners, sorting and signalling. It 
is known that lipid rafts play a regulatory role in diseases of the central nervous system, 
metabolic disorders as well as bacterial and viral infections. 
Taken these three subjects together, this study will focus on the potential intracellular lectin 
vesicular integral-membrane protein (VIP36) and its association with glycoproteins and 
DRMs along the secretory pathway. This protein was extracted from CHAPS DRMs and 
binds to glycoproteins mainly on the mannose-rich D1-arm. Therefore it might play an 
important role as a sorting receptor in the early secretory pathway. 
Advances in enlighten the contribution of new characterized intracellular lectins and their 
interplay with other lectins and glycoproteins along the secretory pathway in special 
membrane domains support our understanding of the sorting machinery in the cell. This might 
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help to enhance our understanding of pathomechanisms which are associated with a defect in 
sorting and trafficking of glycoproteins. 
 
 
1.1 Protein glycosylation 
 
Protein glycosylation plays an important role in numerous cellular functions like development 
(Haltiwanger & Lowe 2004), wound repair (Lackie & Adam 2006), innate immunity (Marth 
& Grewal 2008) and of course quality control and transport of proteins along the secretory 
pathway (Ellgaard & Helenius 2003, Helenius & Aebi 2004, Hebert & Molinari 2007, 
Lederkremer 2009). There are two distinct types of glycosylation which can be found solely 
or in parallel on proteins, namely the N- and O-glycosylation. 
 
1.1.1 N-glycosylation 
 
One of the most common protein modifications is the N-glycosylation (Apweiler et al. 1999). 
In the SWISS-PROT protein sequence data bank, two thirds of all proteins registered have at 
least one potential N-glycosylation site.  
The N-glycosylation needs three cellular compartments: the endoplasmic reticulum (ER), 
Golgi apparatus (Golgi) and cytosol. In the cytosol the mannose donor GDP-mannose is 
synthesized from fructose 6-phosphate. N-glycan assembly starts on the cytoplasmic side of 
the ER were glycans are initially synthesized on a lipid-like molecule termed dolichol 
phosphate. First, N-acetylglucosamine (GlcNAc) is transferred to dolichol phosphate from 
UDP-GlcNAc, catalyzed by GlcNAc-1 phosphotransferase. Then a second GlcNAc is 
transferred on dolichol phosphate, followed by stepwise addition of five mannose residues 
from GDP-mannose. This glycan is further processed after flipping in the luminal side, a 
mechanism which is not fully understood (reviewed in Jaeken & Matthijs 2007). Hereby, the 
dolichol phosphate is translocated across the ER membrane into the lumen of the ER, 
mediated by a flippase. In the lumen, the glycan, linked to dolichol phosphate, is extended by 
the addition of four mannose residues, and three glucoses. The mannose and glucose donors 
are linked to dolichol phosphate and are also build in the cytoplasm. Therefore, they must also 
be flipped across the membrane. 
Membrane and secretory proteins which originate from membrane-bound ribosomes are 
simultaneously translated and translocated into the ER lumen. Here, the newly synthesized 
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proteins immediately become glycosylated by “en bloc” transfer of the Glc3Man9GlcNAc2 
glycan on the side chain of asparagine residues in Asn-X-Ser/Thr motifs by the 
oligosaccharyl-transferase (Kornfeld and Kornfeld 1985, Alberts et al. 2004). In the amino 
acid motif, X represents any amino acid except proline (Khalkhall & Marshall 1975). After 
transfer to the protein, the glycans were further processed in the ER and Golgi. 
The further processing starts with removal of the outer glucose which is located on the D1-
arm of the glycan, by α-glucosidase I in the ER, followed by the action of α-glucosidase II, 
trimming the next glucose. At this state of glycosylation, the monoglucosylated proteins bind 
to CNX or CRT (Vassilakos et al. 1998). While the proteins bind to CNX/CRT they begin to 
fold and are interacting with chaperones which promote its folding (e.g. ERp57). Removal of 
the terminal glucose by α-glucosidase II releases the glycoprotein from the binding of 
CNX/CRT. If the protein is correctly folded it exits the ER on its way to the Golgi. Before 
leaving the ER, many glycoproteins are trimmed by ER α-mannosidase I, which specifically 
removes the terminal α-1,2 mannose from the D1-arm (Herscovics 2001). Incorrect folded 
proteins without terminal glucose are re-glucosylated by the enzyme UDP-glucose 
glycoprotein glucosyltransferase and subsequently get into an additional folding cycle by 
binding to CNX/CRT. In many cases many rounds of deglucosylation and reglucosylation are 
necessary until the protein reaches its native folding. Otherwise when the protein is misfolded 
it is targeted for degradation via the ER-associated degradation pathway (ERAD, Soldà et al. 
2007). 
When correctly folded proteins reach the Golgi the trimming continues, resulting into a 
transformation from the mannose-rich to a complex glycosylated form. First, additional 
mannose residues are removed by the action of α-mannosidase I a, b and c in the cis-Golgi, 
resulting into a Man5GlcNAc2 glycan. GlcNAc is then added to the glycan by N-
acetylglucosaminyltransferase I (GlcNAc-TI). In the medial-Golgi, two mannose residues are 
removed by α-mannosidase II. This step is only initiated when GlcNAc-TI has been active 
previously. Additionally a second GlcNAc is transferred to the glycan by a GlcNAc-T. There 
is also a core modification in this cellular compartment by the addition of fucose, linked to the 
GlcNAc which is adjacent to Asn. When proteins reach the trans-Golgi there is no further 
trimming but an addition of galactose and sialic acid. The addition of the negatively charged 
sialic acid by the CMP-sialic acid transporter is the last step of N-glycosylation and proteins 
exit the Golgi to their final destination (reviewed in Varki et al. 2009). An overview of the 
whole process is shown in figure 1.1. 
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Figure 1.1 Processing and maturation of an N-glycan. Dolichol phosphate transferred the 
Glc3Man9GlcNAc2 glycan to newly synthesized proteins. The glucosidases I and II in the ER remove 
the three glucose residues, and ER mannosidase removes one mannose residue. Additional mannose 
residues are removed in the cis-Golgi until Man5GlcNAc2Asn is generated. The action of GlcNAc-TI 
in the medial-Golgi initiates the first branch of an N-glycan. Alpha-mannosidase II removes two outer 
mannoses. GlcNAc-TII translocates GlcNAc to the branches. The resulting N-glycan is extended by 
the addition of fucose, galactose, and sialic acid to generate a complex N-glycan. Complex N-glycans 
can have more sugars than shown in this figure, including additional residues attached to the core, 
additional branches, branches extended with poly-N-acetyllactosamine units, and different “capping” 
structures. Also shown is the special case of lysosomal hydrolases that acquire a GlcNAc-1-P at C-6 of 
mannose residues on oligomannose N-glycans in the cis-Golgi and the defects of the CHO-Lec cells 
Lec1, Lec2, and Lec8 (modified from Kornfeld & Kornfeld 1985). 
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Typical N-linked oligosaccharides always contain mannose as well as N-acetylglucosamine 
and they have several branches, each terminates with a negatively charged sialic acid residue 
(Lodish et al. 2000). However, the population of sugars attached to glycoproteins depends on 
cell type and physiological status of the cell. Therefore, N-glycans can be very diverse. The 
number of branches can vary as well as the length by addition of tandem repeats consisting of 
GlcNAc and galactose. The final elongation by sialic acid plays an important role since this 
carbohydrate is necessary for many processes, like stabilizing the conformation of proteins 
including enzymes, protecting molecules from attack by proteases, and modulating processes 
involved in signalling, growth, and differentiation (reviewed in Varki et al. 2009). Since sialic 
acid acts as a “mask” for the underlying saccharides, it also prevents binding by intracellular 
lectins that recognize these glycans, regulating cellular processes (reviewed in Varki et al. 
2009). Not all glycans are trimmed to the complex-type but some remain in the mannose-rich 
state. There are also four other N-glycan linkages known, however, the GlcNAc to Asn is the 
most common. 
 
1.1.2 O-glycosylation 
 
The O-glycosylation is initiated by the covalent α-linkage of N-acetylgalactosamine 
(GalNAc) residue from UDP-GalNAc to the hydroxyl group of serine or threonine by an O-
glycosidic bond, catalyzed by a polypeptide N-acetylgalactosaminyltransferase (Lodish et al. 
2000). This type of glycosylation, which takes place in the Golgi, has no defined amino acid 
sequences for attachment of glycans in comparison to the N-glycosylation. However, there are 
certain amino acids which increases the GalNAc addition (e.g. proline), and others which may 
interfere this linkage (e.g. charged amino acids). The role of proline may be to expose Ser or 
Tre in a 〒–turn conformation, leading to more efficient O-glycosylation (reviewed in Varki et 
al. 2009). 
The O-linked glycans consists of short side chains of about 1 to 4 sugar residues (in some 
cases up to 10 residues, Alberts et al. 2004), including galactose, N-acetylgalactosamine, 
fucose or sialic acid (Lodish et al. 2000). In contrast to the initial reactions of N-
glycosylation, no lipid-linked intermediates are involved, and no glycosidases appear to be 
involved in the processing of O-linked glycans. The sugars which are attached to the protein 
depend on the cell type. Figure 1.2 shows an overview of the most common O-glycosylation. 
As mentioned before, it is initiated by the addition of GalNAc to a Ser or Thr of the protein by 
an α-linkage. The next sugar residue is galactose, followed by sialic acid, which are both 
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attached to GalNAc. In an additional step, fucose is transported to the glycan and binds to 
galactose wire α-1,2 linkage (Voet et al. 2002). 
 
 
Figure 1.2 Model of O-glycosylation. The O-glycosylation is initiated by the transfer of N-
acetylgalactosamine (GalNAc) to serine (Ser) catalyzed by the GalNAc-transferase. Sequentially 
galactose (Gal) and sialic acid (SA) are added to GalNAc wire β-1,3 and α-2,6 linkages, respectively. 
Fucose (Fuc) is then linked to Gal by α1,2 linkage (taken from Voet et al. 2002). 
 
 
1.1.3 Defects in glycosylation 
 
The N- as well as the O-glycosylation are important for many proteins for their proper 
folding, sorting and their correct function. For example, O-glycosylation of mucous 
glycoproteins is essential for their ability to hydrate and protect the underlying epithelium in 
respiratory, gastrointestinal and genitourinary tracts. It is also known that mucins (O-
glycosylated proteins) can trap bacteria via specific receptors (reviewed in Varki et al. 2009).  
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In born errors in the glycosylation process in man are termed congenital disorders of 
glycosylation. To date more than 28 congenital disorders of glycosylation are known 
(reviewed in Jaeken & Matthijs 2007). The first patients were reported in 1980. The disorders 
reach from mild to severe diseases, with multisystem or mono-organic disorders. Genetic 
glycosylation disorders cause a wide range of phenotypes, with examples from all specialities. 
Many well known diseases such as Walker-Warburg syndrome and muscle-eye-brain disease 
are caused by a glycosylation defect (reviewed in Jaeken & Matthijs 2007). Some of these 
disorders cause death early after birth, e.g. loss of galactose and sialic acid residues on 
glycoproteins (Lübbehusen et al. 2010). The absence of GlcNAc-TI in mice results into death 
during embryonic development (Ioffe & Stanley 1994), and also the elimination of sialic acid 
production causes embryonic lethality (reviewed in Varki et al. 2009). Mutations, concerning 
sialic acid transport have also been found to be involved in degenerative diseases such as 
atherosclerosis and diabetes, as well as neurological disorders such as Alzheimer`s disease 
(reviewed in Varki et al. 2009).  
For the investigation of glycosylation-defects or glycoprotein function and trafficking, 
different models can be used, such as protein mutants, cell mutants, and glycosylation-
inhibitors. 
Protein mutations were generated in the past, to delete or add glycosylation sites. Herewith 
one could determine whether single glycosylation sites in the protein play a special role or if 
all of them are important for function and trafficking. Several groups could show in the past, 
that deletion of N- and/or O-glycosylation sites resulted in missorting of apical glycoproteins 
to the basolateral surface, whereas addition of N-glycosylation sites targeted the proteins to 
the apical cell surface (Scheiffele et al. 1995, Yeaman et al. 1997, Gut et al. 1998, Benting et 
al. 1999, Jacob et al. 2000, Pang et al. 2004).  
Glycosylation-defective cell lines are also a common tool to investigate glycoprotein function. 
Mutants with a glycosylation defect become resistant to cytotoxic lectins by reducing the 
expression of single sugars or a group of sugars on cell surface glycans. The most common 
cell models are Chinese hamster ovary (CHO)-Lec cells which were established by Stanley et 
al. in 1975. There are many loss-of-function as well as gain-of-function mutants available. 
Glycosylation mutants help to define the genes which encode for the affected transferases or 
glycosidases. They also provide an insight into the functions of glycosylation in cells and 
tissues and provide a model for human born errors in metabolism and disease. The restriction 
in this case is the restriction to the cell type and organism from which it was isolated 
(reviewed in Varki et al. 2009). 
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The usage of glycosylation-inhibitors is common in research of glycoproteins, since many are 
known and commercially available. They are mostly small molecules which are taken up 
readily by a variety of cell types. They can also be absorbed through the gut, which provides 
an opportunity for investigation of whole organisms and to design drugs for the treatment of 
human glycosylation-diseases and -disorders. Tunicamycin, for example, is an inhibitor of 
dolichol phosphate-GlcNAc assembly, and thereby prevents N-glycosylation. 1-
deoxynoijrimycin (dNM) retains the three glucose residues on the N-linked glycan and 
usually loses one or two mannose residues as the protein pass through the ER and medial-
Golgi. By the use of 1-deoxymannoijrimycin (dMM), the action of α-mannosidase I in the cis-
Golgi can be blocked, resulting in a Man8GlcNAc2 glycan on mature proteins. Many studies 
were carried out with these glycosylation-inhibitors to investigate several glycoprotein 
functions (Gut et al. 1998, Huet et al. 1998, Naim et al. 1999, Alfalah et al. 2002, Vagin et al. 
2004, Delacour et al. 2005). 
 
1.1.4 Glycoproteins 
 
Dipeptidyl peptidase IV (DPPIV) 
 
Dipeptidyl peptidase IV (DPPIV/ CD26) is a type II transmembrane glycoprotein. This 
multifunctional protein belongs to the family of serine proteases and cleaves N-terminal 
dipeptides from polypeptides with proline or alanine next to last position (Havre et al. 2008). 
It is widely expressed on the surface of epithelial, endothelial, and lymphoid cells (De Abbott 
et al. 1994, De Meester et al. 1999). However, a soluble form can also be found in the plasma 
(Iwaki-Egawa et al. 1998). The human DPPIV consists of 766 amino acids (Darmoul et al. 
1992, Misumi et al. 1992). However, the molecular mass of DPPIV depends on the species, 
tissue, and its stage of glycosylation and range between 100 kDa and 150 kDa (Ikehara et al. 
1994). The molecular mass for the mannose-rich (DPPIVh) and the mature form (DPPIVc) in 
Caco-2 cells are 100 kDa and 124 kDa (Matter & Hauri 1991), in CHO cells 100 kDa and 110 
kDa (Hong et al. 1989), respectively. DPPIV is transported to the apical membrane on two 
distinct pathways, either directly from the trans-Golgi network (TGN) or through the 
transcytotic pathway across the basolateral membrane (Le Bivic et al. 1990, Matter et al. 
1990, Low et al. 1991). The transmembrane form of DPPIV exists as a homodimer (Jascur et 
al. 1991). This dimerization is essential for its enzymatic activity (De Meester et al. 1992).  
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In human cells, it has nine potential N-glycosylation sites (Misumi et al. 1992) and is also 
highly O-glycosylated at the Ser/Thr-rich stalk domain (Matter & Hauri 1991). In CHO cells, 
eight N-glycosyl chains are acquired (Hong et al. 1989). The N- and O-glycosylation is 
important for DPPIV to reach the apical surface, since inhibition of glycosylation results in 
transport to the basolateral membrane (Fan et al. 1997, Huet et al. 1998, Naim et al. 1999). 
DPPIV is associated with lipid rafts and this association is important for its proper sorting 
(Alfalah et al. 2002, Alfalah et al. 2005). Stechly et al. (2009) found that the lectin galectin-4 
is involved in sorting of DPPIV into Triton X-100 rafts and apical delivery. 
 
Sucrase-isomaltase (SI) 
 
Sucrase-isomaltase (SI) (EC 3.2.1.48-10) is a type II transmembrane glycoprotein (Blobel 
1980) which consists of 5 functional domains including the two subunits sucrase and 
isomaltase (Fig. 1.3). It belongs to the family of intestinal disaccharidases or hydrolases and is 
located at the apical membrane in the microvilli of enterocytes and Caco-2 cells. Its cDNA 
encodes for a sequence of 1827 amino acids and it is synthesized in the ER as a common 
precursor protein (pro-SI) (Hunziker et al. 1986, Naim et al. 1988b). On the way through the 
ER and Golgi this precursor is modified and provides five O-glycosylation sites as well as 
eight N-glycosylation sites on each subunit. Seven of the N-glycosylation sites of sucrase are 
complex glycosylated whereas the eights site remains in the mannose-rich form (Naim et al. 
1988b). After these modifications, pro-SI is transported directly to the apical cell surface (Le 
Bivic et al. 1990, Matter et al. 1990). For the correct sorting of SI, the O-glycosylation as well 
as its association with lipid rafts is required (Alfalah et al. 1999, Jacob et al. 2003).  
 
Isomaltase SucraseN C
TrypsinSer/Thr Stalk
Signal sequence/
Membrane anchor
 
Figure 1.3 Model of sucrase-isomaltase. Sucrase-isomaltase consists of five subunits. The N-
terminal domain is directed into the lumen of the cell. The signal sequence, which functions also as a 
membrane anchor, is followed by the Ser/Thr rich stalk domain. The two subunits isomaltase and 
sucrase are directed together with the stalk domain into the lumen of the gastrointestinal tract.  
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When pro-SI reaches the plasma membrane it is proteolytically cleaved by pancreatic trypsin 
to isomaltase with a size of 145 kDa and sucrase with a size of 130 kDa (Hauri et al. 1985, 
Naim et al. 1988b), however the two subunits remain connected (Hunziker et al. 1986). The 
sucrase subunit cleaves sucrose at position α-1,2 to glucose and fructose, whereas isomaltase 
cleaves isomaltose at position α-1,6 and produces also glucose. The monosaccharide glucose 
can then be absorbed by the cells. 
 
 
1.2 Lectins 
 
Lectins are defined as proteins that significantly recognize and bind to glycans without 
catalyzing a modification of the glycan. The first lectin was discovered by Stillmark in 1888. 
He found out that seed extracts of the plant Ricinus communis contain a toxin that can 
agglutinate erythrocytes (reviewed in Varki et al. 2009) and termed it due to its function 
agglutinate. This protein family was later renamed in lectins from the Latin word legere, 
meaning to select, and become important members of the general class of glycan-binding 
proteins.  
Lectins can be found in plants, animals and bacteria. They recognize specific terminal sugar 
residues on glycans linked to proteins or lipids with a specific binding site, namely the 
carbohydrate recognition domain (CRD). There are different classes of lectins known (e.g. R-
type, L-type), characterized by its origin or properties of CRD. L-type lectins, for example, 
were first extracted from the seeds of legominous plants. However, this class of lectins has 
also representatives in mammalian cells (reviewed in Varki et al. 2009). 
Many L-type lectins are well defined and used as tools for analytical and biomedical 
procedures due to their variety of carbohydrate-binding specificities. Their structure consists 
of two antiparallel pleated sheets and a CRD (Sharon & Lis 1990). This CRD forms two 
cavities, one containing Ca
2+
 or Mn
2+
 ions, the other containing the monosaccharide. In 
between these two cavities, an aspartate and an asparagine are located, which side chains bind 
Ca
2+
 ions and provide hydrogen bonds to the monosaccharide (Sharon & Lis 1990, Shaanan et 
al. 1991)  
In plants, lectins help to find symbiotic partners or defend against bacteria. In mammalian 
cells many intracellular lectins are involved in quality control, sorting and transport of 
glycoproteins and glycolipids.  
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1.2.1 Mammalian intracellular lectins along the secretory pathway 
 
It is hypothesized that the glycans which are attached to glycoproteins represent “cellular 
addresses”, which mediate progression through the secretory pathway and define their final 
destinations (Helenius & Aebi 2001). This predicts the existence of compartment-specific 
receptors that recognize and bind different oligosaccharides. Such receptors have been 
identified as intracellular lectins.  
 
Intracellular lectins play important roles in transport and sorting along the secretory pathway: 
Calnexin (CNX) and calreticulin (CRT) act as molecular chaperones (Ou et al. 1993, Nauseef 
et al. 1995, Ware et al. 1995), ERGIC 53 kDa protein (ERGIC-53) functions as a transport 
cargo receptor (Appenzeller et al. 1999), VIP36-like protein (VIPL) is proposed to play a role 
in protection of folded high mannose-type glycoproteins (Kamiya et al. 2008), and mannose-
6-phosphate receptor recognizes the marker for lysosomal enzymes (Dahms et al. 1989). 
 
These receptors share a general domain organization. They consist of a luminal (exoplasmic) 
domain which contains one or multiple carbohydrate recognition domains (CRD), a single 
transmembrane domain, and a short cytoplasmic domain with sorting signals that can interact 
with cytosolic coat components and mediates sorting within the secretory pathway. 
 
Calnexin (CNX) and calreticulin (CRT) 
 
CNX and CRT are ER-resident proteins. CNX is an 88 kDa type I transmembrane protein, 
which mainly interacts with N-glycans close to the ER membrane, whereas CRT is a soluble 
protein of 55 kDa that binds proteins present in the lumen or to those that have large 
lumenally oriented domains. Both are L-type lectins and require one glucose and three 
mannose residues on the D1-arm to recognize and bind to glycoproteins (Ware et al. 1995, 
Spiro et al. 1996, Vassilakos et al. 1998). Their binding activity is sensitive to changes in Ca
2+
 
concentration. The structure of CNX consists of two main components: a globular lectin 
domain and an extended arm-like domain, the so called P-domain (Schrag et al. 2001). The 
lectin domain mainly consists of a 〒-sandwich formed by two curved 〒-sheets, similar to 
legominous plant lectins, and a calcium binding site that stabilizes the protein (Brockmeier & 
Williams 2006). The P-domain interacts with the thiol-oxidoreductase ERp57 which is 
involved in folding of glycoproteins (Frickel et al. 2002, Kozlov et al. 2006). The lectin and 
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P-domain are also preserved in CRT and are similar to that of CNX; additionally it has a 
KDEL ER-retention signal at the C-terminus (Peterson & Helenius 1999, Kozlov et al. 2010). 
The structure of CRT is most similar (33 % sequence identity of lectin domain) to CNX, but 
shares also similarities to Emp47p (a homolog of ERGIC-53 in yeast), ERGIC-53 and VIP36, 
which are all recognizing the D1-arm for carbohydrate binding (Kozlov et al. 2010). 
 
ERGIC-53 
 
ERGIC-53 is a type I transmembrane protein which is associated with the ER-Golgi 
intermediate compartment (ERGIC, Hauri & Schweizer 1992) and recycles between the ER 
and ERGIC (Lippincott-Schwartz et al. 1990). Its cytoplasmic carboxyl terminus contains the 
ER-retention signal KKFF, where the dilysine part is recognized by COPI coatomer complex. 
This enables the coated vesicles to be recycled from the Golgi back to the ER (Itin et al. 
1995b). On the other hand, the diphenylalanine direct COPII coated vesicles to ER exit sites 
by binding to the COPII coatomer (Kappeler et al. 1997). ERGIC-53 is a mannose specific, 
calcium dependent lectin which is homologue to leguminous plant lectins (Arar et al. 1995, 
Itin et al. 1996), belonging to the family of L-type lectins with a long half-life of 
approximately 30 h (Neve et al. 2003). It is known that this protein forms homodimers or 
homohexamers which is not necessary for interacting with cargo but to exit the ER 
(Appenzeller et al. 1999). ERGIC-53 binds high-mannose type oligosaccharides (at the D1-
arm) with a broad specificity at pH 7.4 but not at slightly lower pH (Kamiya et al. 2005) and 
requires the amino acids A120, D121 and N156 for carbohydrate binding (Itin et al. 1996). It 
is known that this lectin acts as a cargo receptor for a limited set of glycoproteins including 
cathepsin C (Vollenweider et al. 1998), cathepsin Z (Appenzeller et al. 1999), blood 
coagulation factors V and VIII (Nichols et al. 1998, Moussalli et al. 1999), α-1-antitrypsin 
(Nyfeler et al. 2008), and immunoglobulin M (Cortini & Sitia 2010). Dysfunctional ERGIC-
53 leads into a bleeding disorder caused by a deficiency of coagulation factors V and VIII 
(Nichols et al. 1998). 
 
VIPL 
 
VIPL is an ER-resident protein (Nufer et al. 2003, Neve et al. 2003). It was first identified in 
2003 and named VIPL since it has 68 % similarity to VIP36 (Nufer et al. 2003). This type I 
transmembrane protein has a predicted size of 35.6 kDa and contains one N-glycosylation site 
INTRODUCTION 
28 
which is high mannose-type glycosylated (Neve et al. 2003). It is expressed in many cell 
types and tissues, having a very short half-life of about 30 min (Neve et al. 2003). The 
existence of an ER-retrieval signal (RKR) at its cytoplasmic tail leads to its ER localization 
(Nufer et al. 2003, Neve et al. 2003). The binding of VIPL to glycoproteins is calcium 
dependent and reaches its maximum at pH 7.4, which refers to the pH in the ER (Yamaguchi 
et al. 2007). It has binding specificity for the D1-arm of high-mannose N-liked glycans, since 
glucosylation of the D1-arm inhibits it’s binding (Yamaguchi et al. 2007). Overexpression of 
this lectin results into a striking redistribution of ERGIC-53 to the ER (Nufer et al. 2003). 
Neve et al. (2003) found that VIPL binds to glycoproteins of different size (35 and 250 kDa) 
and Yamaguchi et al. (2007) identified porcine thyroglobulin as a binding partner, suggesting 
that it may be involved in the regulation of export from the ER of a subset of glycoproteins. 
Another potential function is to prevent degradation of folded proteins by protection from 
demannosylation and interaction with proteins of the ERAD pathway (Kamiya et al. 2008, 
Yamamoto 2009), but to date its function is not fully understood.  
 
Other lectins along the secretory pathway 
 
The mannose-6-phosphate receptor operates in the TGN. It recognizes terminal mannose-6-
phosphate residues on N-linked carbohydrates of glycoproteins (Fig. 1.1) and sort them into 
clathrin-coated vesicles destined for endosomes (Kornfeld 1992). The cargo is then released 
in the endosome and the receptor recycles back to the TGN for an additional round of sorting 
and transport. 
A domain homolog to mannose-6-phosphate receptor was found in the ER protein 
osteosalcoma 9 (OS-9) (Kimura et al. 1998, Munro 2001). This lectin binds to terminal 
mannose of the C-arm of high mannose-type glycans and is involved in the ERAD pathway 
(Hosokawa et al. 2009, Mikami et al. 2010). Together with the lectin XTP3-transactivated 
gene B protein precursor it is involved in translocation for ubiquitination of misfolded 
proteins (reviewed in Anelli and Sitia 2008). 
Another lectin which is also involved in ERAD is the ER-degradation enhancing α-
mannosidase like protein (EDEM, Hosokawa et al. 2001). This protein has binding specificity 
for high mannose-type glycans, sorting misfolded proteins to the ERAD pathway (Hosokawa 
et al. 2001, Jacob et al. 2001). 
The two Lectins of the galectin family galectin-3 and galectin-4 play also a role in the 
secretory pathway. They are localized in the late secretory pathway beyond the Golgi and are 
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required for apical protein sorting of different glycoproteins (Delacour et al. 2005, Delacour et 
al. 2006, Stechly et al. 2009). 
 
1.2.2 Lectin-interplay in the early secretory pathway 
 
The working model of intracellular lectins in the early secretory pathway so far is shown in 
figure 1.4.  
 
 
Figure 1.4 Intracellular lectins involved in quality control and transport of glycoproteins in the 
ER. The quality control pathway is classified into three kinds of reactions: folding of unfolded 
proteins, ER-associated degradation of misfolded proteins, and transport and sorting of correctly 
folded proteins. These reactions are regulated by several intracellular lectins, which recognize N-
glycans attached to glycoproteins as tags. UGGT: UDP-glucose: glycoprotein glycosyltransferase, 
EDEM: ER-degradation enhancing α-mannosidase like protein, OS-9: osteosalcoma-9 protein, XTP3-
B: XTP3-transactivated gene B protein precursor, ERGIC-53: ER-Golgi intermediate compartment 53 
kDa protein, MCFD2: multiple coagulation factor deficiency 2 protein, VIPL: VIP36-like protein 
(modified from Yamamoto 2009). 
 
CNX and CRT bind to monoglucosylated N-linked glycans on newly synthesised proteins and 
release them when the terminal glucose is processed. When proteins are not correctly folded, 
lectins, which are involved in the ER-associated degradation like EDEM and OS-9, bind to 
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these proteins. In the ERAD process, the misfolded proteins are translocated across the ER-
membrane, conjugated with ubiquitin, and targeted to the proteasome for destruction in the 
cytoplasm.  
Correctly sorted proteins are bound by VIPL which prevent the degradation process.  
Some of the proteins are then handed to ERGIC-53 which transports them out of the ER in 
COP II coated vesicles which fuse to the ERGIC which is located near the cis-Golgi 
(Bannykh et al. 1998, Klumperman et al. 1998, Horstmann et al. 2002). Afterwards, ERGIC-
53 recycles back to the ER. The ERGIC plays an important role in the sorting of proteins 
since it receives anterograde cargo coming from the ER and on the other hand, is involved in 
retrograde transport of escaped proteins back to the ER (Klumperman et al. 1998, Martinez-
Menarguez et al. 1999). Proteins that have reached the ERGIC are further transported in a 
microtubule-dependent manner to the cis-Golgi (Saraste & Svensson 1991, Presley et al. 
1997). 
Another lectin which is proposed to play a role in the secretory pathway is vesicular integral-
membrane protein (VIP36) which is discussed in the next paragraph. 
 
1.2.3 Vesicular integral-membrane protein (VIP36) 
 
Vesicular integral-membrane protein (VIP36) is an intracellular L-type lectin of 36 kDa, 
which has homologies to leguminous plant lectins (Fiedler et al. 1994). This type I 
transmembrane protein consists of 322 amino acids and has a CRD in its luminal part (Fig. 
1.5). The CRD exhibits optimal binding affinities for glycoproteins that leave the CNX/CRT 
cycle in the ER and yet do not undergo trimming of the D1 mannosyl branch in the cis-Golgi 
(Kamiya et al. 2005). However it can also bind to other high mannose type glycans but with a 
lower binding affinity (Kamiya et al. 2005). The high specificity for deglucosylated D1 
branch is governed by a single aspartate residue in its sugar-binding pocket (Kamiya et al. 
2008). It was also reported that VIP36 binds to GalNAc found on O-linked glycans (Fiedler & 
Simons 1995). 
VIP36 contains a c-terminal endocytosis signal (KRFY) similar to that of ERGIC-53 (Itin et 
al. 1995a). Moreover it shares 46 % similarity of its CRD with ERGIC-53. The human gene 
encoding for VIP36 is located on chromosome 5 and has a total length of 14.9 kb with 8 
exons (Nufer et al. 2003). 
It is ubiquitously expressed in epithelial and non-epithelial tissues, having a half-life of 
approximately 5 h (Neve et al. 2003) and carrying one N-glycosylation site (Fiedler & Simons 
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1995), which is complex glycosylated (Füllekrug et al. 1999). VIP36 binds mainly to 
membrane proteins but can also bind secretory proteins and has its maximal binding activity 
at 37°C and pH 6 (Hara-Kuge et al. 1999) which indicates a localization manly in the cis-
Golgi. 
 
c
ba
 
Figure 1.5 Structure of VIP36. a: The type I transmembrane protein VIP36. It consists of a short 
cytoplasmic domain followed by the transmembrane domain. The luminal/exoplasmic domain carries 
the CRD and consists of the amino acids 45-322. Here, the model of VIP36 binding to salvary α-
amylase carrying Man8GlcNAc2 in rat secretory vesicles is shown. b: Ribbon model of the overall 
structure of the luminal/exoplasmic domain of VIP36. The secondary structures are highlighted 
(concave ˟-sheets: yellow, convex ˟sheets: blue, ˟-hairpin: cyan, ˟-sheet between stalk domain and 
one of the CRD loops: magenta, helices: red). The loops of the CRD and the stalk domain are coloured 
gray and green, respectively. c: the high mannose-type glycan of VIP36 indicated by a stick model. 
Modelled D2- and D3-arms and N-linked chitobiose moiety of the high mannose-type glycan are 
shown in purple, types of glycosidic linkages are indicated (modified from Satoh et al. 2007). 
 
Fiedler et al. (1994) first isolated VIP36 from CHAPS detergent resistant membranes (DRMs) 
or glycolipid rafts from Mardin-Darby canine kidney (MDCK) cells containing apical marker 
proteins. They found a localization of this lectin in the Golgi, endosomal and vesicular 
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structures and to the apical and basolateral cell surface (Fiedler et al. 1994). However, 
Füllekrug et al. (1999) found that this lectin is also localized to the early secretory pathway, 
by showing a significant overlap of VIP36 with ERGIC and COPI vesicles and that it is 
cycling between the ER and Golgi. Further, by modifying the methods of Fiedler et al. (1994) 
to isolate DRMs, they showed that VIP36 is not associated with DRMs of the Golgi, 
suggesting that VIP36 is unlikely to play a role in formation of glycolipid rafts (Füllekrug et 
al. 1999). The cycling of VIP36 leads to the suggestion that VIP36 recognizes glycoproteins 
that have escaped trimming by cis-Golgi α-mannosidase I and recycle them back for an 
additional trimming (Hauri et al. 2000). However VIP36 seems to have no ability to 
distinguish correctly folded from misfolded proteins (Mikami et al. 2010). Dahm et al. (2001) 
showed that VIP36 traffics with cargo only in the early secretory pathway, separating at the 
level of the Golgi-apparatus. However, secretory glycoproteins recognized by VIP36 were 
secreted 2-fold more efficient from the apical membrane than from the basolateral membrane 
(Hara-Kuge et al. 2002). 
VIP36 interacts with the apical secretory glycoprotein clusterin (Hara-Kuge et al. 2002), α-
amylase in rat parotid gland cells (Hara-Kuge et al. 2004) and, partial colocalize with ERGIC-
53 in transport vesicles (Shimada et al. 2003b). A carbohydrate-independent interaction could 
be shown between VIP36 and immunoglobulin-binding protein (BiP) over a long period of 
time in the ER (Nawa et al. 2007). Since VIP36 is Endo H resistant when interacting with 
BiP, it might be relocated to the ER from the Golgi after complex glycosylation. An 
interaction with BiP in the early secretory pathway indicates that VIP36 plays a role in early 
sorting events. Alpha-1-antitrypsin was also found as cargo for VIP36 between the ER and 
Golgi (Reiterer et al. 2010). This binding was increased when complex N-glycosylation was 
prevented (Reiterer et al. 2010). Therefore they suggest that VIP36 may function as a post-ER 
quality control of α-1-antitrypsin. 
 
 
1.3 Lipid rafts 
 
In the last decades, there were a lot of studies concerning the composition of the membrane 
bilayer which was first described as a continuous two-dimensional fluid phase, acting as a 
neutral solvent for membrane proteins in which all molecules diffuse freely (Singer & 
Nicolson 1972). To date, it is known that lipids are distributed asymmetrically between the 
outer and inner leaflets of the bilayer (Van Meer 1989). This membrane model leads to a 
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different organization of membrane components on the lateral axis, leading to a variety of 
lipid-lipid, lipid-protein, and actin cytoskeleton interactions (Anderson & Jacobson 2002, 
Edidin 2003, Kwik et al. 2003).  
 
1.3.1 Structure and function of lipid rafts 
 
The membrane bilayer is separated into a lipid-disordered (ld) and a lipid-ordered (lo) phase 
(Brown & London 1998). The lo-phase is enriched in cholesterol and sphingolipids with their 
saturated fatty acids, and saturated glycerophospholipids. The structure of their hydrophobic 
parts allows them to pack more tightly than the linked unsaturated glycerophospholipids. 
Therefore they establish a more ordered state (Brown & London 1998). These phases are 
termed lipid rafts (or lipid microdomains, membrane microdomains, DRMs), which have been 
investigated from several groups in the last two decades (Simons & Van Meer 1988, Brown & 
Rose 1992, Simons & Ikonen 1997). Pike (2006) defined them as small (10-200 nm), highly 
dynamic, sterol and sphingolipid-enriched microdomains that compartmentalize cellular 
processes. Size and composition of lipid rafts varies depending on cell type (Schuck et al. 
2003), nutrition conditions (Peretti et al. 2005) and differentiation stage of the cell (Fitzner et 
al. 2006). 
Lipid rafts are dynamic structures. They are dispersed in membranes but can move in it and 
diffuse laterally to build clusters (Henderson et al. 2004). It has been reported, that they can 
cluster into larger structures to bring signalling molecules together to initiate intracellular 
signalling. They might play a role as “reaction vessels”, increasing the chance that two 
specific proteins of low concentration will meet on the membrane (Nicolau et al. 2006).  
Phase separation of lipid rafts has been demonstrated in model membranes and biological 
membranes; however the length and time scales on which this phase separation occurs are still 
a matter of debate (Simons & Ikonen 1997, Edidin 2003, Kwik et al. 2003, Kusumi et al. 
2004). Moreover, it is still put into question if DRMs, lipid rafts and lo phases are 
synonymous, although it was found that they are all dependent on cholesterol and are 
organized almost by the same principles (reviewed in Lindner & Naim 2009). 
Many proteins associate with lipid rafts, like GPI-anchored proteins, transmembrane 
signalling proteins (e.g. tyrosine kinases), and acylated proteins (e.g. Ser family). Their GPI-
anchor or other signals or structural features in their transmembrane domain enable them to 
associate with lipid rafts. Some proteins require oligomerization or ligand binding for sorting 
into these microdomains (Holowka & Baird 2001, Paladino et al. 2004). It is also known that 
INTRODUCTION 
34 
proteins stabilize lipid rafts through their association with the cytoskeleton (Nakada et al. 
2003). Several growth factor receptors including epidermal growth factor receptor, insulin 
receptor, and the nerve growth factor receptor are localized in membrane microdomains. 
Their signalling functions are significantly modulated by glycolipids (reviewed in Varki et al. 
2009). The glycosphingolipids may play a role in the flow of information from the outside to 
the inside of cells, which is supported by the observation that antibody-induced 
glycosphingolipid clustering activates lipid raft-associated signalling (reviewed in Varki et al. 
2009). Other proteins also need the association for signal transduction like IgE in allergic 
response and T-cell antigen receptor signalling (Field et al. 1995, Janes et al. 2000). Correct 
targeting of various apically sorted proteins such as DPPIV or SI is dependent on an 
association with lipid rafts, whereas basolateral sorted proteins are normally not included 
(reviewed in Schuck & Simons 2004). 
 
 
Figure 1.6 Structure of lipid rafts. Lipid rafts (blue bilayer) are specialized membrane domains 
containing high concentrations of cholesterol, sphingomyelin, and gangliosides. They are also 
enriched in phospholipids that contain saturated fatty acyl chains (straight lines in lipid tails). This 
composition results in lateral phase separation and the generation of a lipid ordered (lo) phase. Bulk 
plasma membrane (gray) contains less cholesterol, sphingomyelin and gangliosides, and more 
phospholipids with unsaturated fatty acyl chains. As a result, it is more fluid than lipid rafts. A variety 
of proteins partition into lipid rafts: glycosylphosphatidylinositol-anchored proteins (GPI), 
transmembrane proteins (TM), dually acylated proteins (Acyl). As shown in this figure, not all lipid 
rafts have the identical protein or lipid composition (Raft 1 and Raft 2). PC: phosphatidylcholine, PE: 
phosphatidyletanolamine, PS: phosphatidylserine, PI: phosphatidylinositol, SPM: sphingomyelin, 
Chol: cholesterol, Gang: gangliosides (taken from Pike 2003).  
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Since lipid rafts are involved in intra- and intercellular sorting and signalling, many studies 
were conducted in focus on diseases, where lipid microdomains play a role. These studies 
showed that lipid rafts are involved in infectious diseases (e.g. HIV infection, Campbell et al. 
2001), prion-related diseases and cancer (reviewed in Simons & Ehehalt 2002). 
All these features of lipid rafts make them a very important tool for proteins and lipids in 
signalling, transport and sorting. 
 
1.3.2 Detergent resistant membranes (DRMs) 
 
The advantage to extract membrane microdomains is their ability to resist extraction with 
non-ionic detergents (e. g. Triton X-100) at 4°C and floating to lighter fractions on sucrose-
density gradients (Brown & Rose 1992, Brown & London 1998). This widely established 
method to isolate lipid rafts has led to the term Detergent Resistant Membranes (DRMs, 
Brown & Rose 1992) which encompasses several membrane populations that share the 
common ability to remain insoluble in various detergents. Most common is the isolation of 
Triton X-100 DRMs. However, other non-ionic detergents such as CHAPS, Brij, Lubrol WX 
and Tween 20 are also used to isolate different membrane populations. These detergents have 
different strength to solubilise DRMs and have different lipid and protein compositions 
(Drobnik et al. 2002, Schuck et al. 2003, Alfalah et al. 2005). This diversity of lipid and 
protein composition is also shown in membranes of different cellular compartments, which 
leads to the theory that the DRMs, isolated by different detergents, originate from different 
cellular compartments and are not restricted to the plasma membrane. Several studies showed 
the existence of DRMs in ER membranes, isolating DRMs which contain early biosynthetic 
forms of proteins (Paladino et al. 2004, Browman et al. 2006, Hein et al. 2009), and 
identifying them as early sorting platforms (Alfalah et al. 2005).  
Delauney et al. (2008) isolated DRMs of the Golgi with different detergents, namely Triton 
X-100 and Lubrol WX. They found that Lubrol WX DRMs contain more lipids of the inner 
membrane leaflet, whereas Triton X-100 DRMs represents more the outer membrane leaflet 
(Delauney et al. 2008). Other studies also showed that these two distinct DRMs exist in the 
same membrane, by isolating proteins from Lubrol WX DRMs which are soluble in Triton X-
100 DRMs (promimin: Roper et al. 2000, prostate-specific membrane antigen: Castelletti et 
al. 2008). 
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1.4 Aim of the study 
 
The sorting machinery along the secretory pathway is a complex of many proteins which are 
responsible for the correct sorting, folding and routing through the cellular compartments. The 
correct sorting of proteins plays a crucial role for their physiological functions. There are 
many diseases known such as congenital sucrase-isomaltase deficiency, cystic fibrosis, glucose-
galactose malabsorbtion, and congenital lactase deficiency (Naim et al. 1988a, Riordan et al. 
1989, Turk et al. 1991, Kuokkanen et al. 2006), which are caused by missorted and misfolded 
proteins which are dysfunctional. Therefore, it is important to get a better understanding of 
the sorting machinery along the secretory pathway, where many intracellular lectins are 
involved. 
In the past years many lectins were identified which play a role in ER quality control (e.g. 
calnexin, calreticulin) or for the transport between cellular compartments (e.g. ERGIC-53, 
mannose-6-phosphate receptor). But not for all lectins which have been identified in the 
secretory pathway, their function is fully defined. One of these lectins is VIP36. It has been 
shown that it is mainly localized in the cis-Golgi but can also be found in the ER, ERGIC or 
even at the cell surface (Fiedler et al. 1994, Füllekrug et al. 1999). Kamiya et al. (2005) found 
that VIP36 has high binding affinities for glycoproteins that leave the CNX/CRT cycle in the 
ER and yet do not undergo trimming of the D1 mannosyl branch in the cis-Golgi, but that it is 
also able to bind other glycoforms. 
The general aim of the study was to characterize the function and localization of the 
intracellular lectin VIP36.  
The following specific aims were investigated: 
 
1. Since only a few glycoproteins have already been identified as cargo for VIP36, I 
wanted to identify additional interaction partners which might act as cargo for VIP36 
in different cell lines. Hara-Kuge et al. found in 1999 and 2002, that VIP36 recognizes 
more apical than basolateral sorted glycoproteins, which are associated with the cell 
membrane. Therefore, I focused on apical transmembrane glycoproteins as VIP36 
interaction partners.  
2. Moreover, I wanted to investigate when interaction of VIP36 and cargo takes place 
and if different glycoforms of the proteins play a role in this process. For this, pulse 
chase experiments as well as glycosylation-inhibitors and glycosylation-defective cell 
lines were used. 
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3. DRMs or lipid rafts are found to function as a platform for signalling and sorting 
along the secretory pathway. Therefore, many proteins need the association with 
DRMs for a proper function and sorting, and further to get in contact with the right 
interaction partners. Since VIP36 was isolated from CHAPS DRMs, I was wondering 
if there is an association with other types of DRMs along the secretory pathway. Thus, 
I wanted to show where VIP36 might localize along the secretory pathway when 
interacting with cargo and if DRMs might function as a platform for interacting with 
glycoproteins for this lectin. To investigate the association of VIP36 with DRMs and 
its cargo at different stages of glycosylation, I used glycosylation-defective cell lines. 
To proof the hypothesis that obtained differences are not only due to a different lipid 
composition of DRMs in the defective cell lines, lipid analysis followed by statistical 
analysis of the different DRMs were conducted. 
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2. Materials and Methods 
 
 
2.1 Materials 
 
All solutions, buffers and plastic ware used for cell culture were autoclaved (121°C, 1 bar, 20 
min) before usage. Reagents were at least of p. a. quality. 
 
2.1.1 Used chemicals 
 
Acetic acid glacial     Roth, Karlsruhe, Germany 
Acetic acid methyl acetate    Roth 
Acrylamide, Rotiphorese Gel30   Roth 
Ammonium chloride (NH4Cl)   Fluka, Steinheim, Switzerland 
Ammoniumperoxodisulfate (APS)   Merck, Darmstadt, Germany 
Bovine serum albumine (BSA)   PAA, Pasching, Austria 
Chloroforme      Roth 
Coomassie Brilliant Blue    SERVA, Heidelberg, Germany 
Copper sulphate (CuSO4 x 5 H2O)   Merck 
1-Deoxymannojirimycin hydrochloride (dMM) Sigma, Taufkirchen, Germany 
1-Deoxynojirimycin hydrochloride (dNM)  Sigma 
Diethyl ether      Roth 
Dimethylsulfoxide (DMSO)    Fluka 
Dithiolthreitol      Sigma 
Ethanol      Roth 
Ethylendiamintetraacetic acid (EDTA)  Roth 
Fetal calf serum (FCS)    Gibco, Eggenstein, Germany 
FuGENE
® 
HD Transfection Reagent   Roche, Mannheim, Germany 
Geneticin
®
 (G418-Sulphate)    PAA 
Glycerol      Sigma 
L-glutamine      PAA 
Lubrol WX      Merck 
2-Mercaptoethanol     Sigma 
Methanol      Roth 
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Mowiol 4-88      Calbiochem, an affiliate of Merck 
N-hexane      Roth 
N,N,N’,N’-Tetramethylethylendiamine (TEMED) Roth 
Paraformaldehyde     Fluka 
Peniciline-streptomycine    PAA 
Potassium chloride (KCl)    Roth 
Potassium dihydrogen phosphate (KH2PO4)  Roth 
1-Propanol      Roth 
Protease inhibitor:  
Antipain, Aprotinin, Leupeptin, Pepstatin,  Sigma 
Trypsin inhibitor 
PMSF      Boeringer Ingelheim, Ingelheim, Germany 
Protein assay concentrate  Bio-Rad Laboratories, Munich, Germany 
Protein A-Sepharose      Amersham Biosciences GE Healthcare, 
Freiburg, Germany 
Saponin      Sigma 
Sodium chloride (NaCl)    Roth 
Di-Sodium hydrogen phosphate anhydrous  Roth 
(Na2HPO4) 
Sodium hydroxide (NaOH)    Merck 
Sodium dodecyl sulphate (SDS)   Roth 
Sucofin skim milk powder    TSI GmbH & Co. KG, Zeven, Germany 
Sucrose      MP Biomedicals LLC, Ohio, USA 
SuperSignal ELISA Femto Maximum  Perbio Science, Bonn, Germany 
Sensitivity Substrate 
Tris-HCL      Roth 
Triton X-100      Sigma 
Trypsin for cell culture    PAA 
Trypsin (from bovine pancreas)   Sigma 
Tween 20      Roth 
[
35
S]methionine     Amersham Biosciences GE Healthcare 
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2.1.2 Used antibodies 
 
Primary antibodies: 
Vesicular integral-membrane protein: polyclonal rabbit Ab sc-67131 (H-90), 200µg/ml 
WB: 1:330, IP: 1µg  
(Santa Cruz Biotechnology, Heidelberg, Germany) 
Dipeptidyl peptidase IV: mAb HBB 3/775/42 (Hauri et al. 1985) 
WB: 1:2000, IP: 1 µg 
Sucrase-isomaltase:  mAb HBB 3/705/60 (Hauri et al. 1985) 
WB: 1:330, IP: 1µg  
mAb HSI2 (Beaulieu et al. 1989) 
IP: 1 µg  
Lactase-phlorizin hydrolase:  mAb mLac 10 (Maiuri et al. 1991) 
WB: 1:1000  
mAb HBB 1/909 (Hauri et al. 1985) 
IP: 1 µg  
Aminopeptidase N: mAb HBB 3/153/63  
IP: 1 µg (Hauri et al. 1985) 
Flotillin-2: mAb sc-28320 (B-6), 200µg/ml 
WB: 1:1000  
(Santa Cruz Biotechnology) 
RhoA: mAb sc-418 (26C4), 200µg/ml  
WB: 1:1000  
(Santa Cruz Biotechnology) 
 
Secondary Antibodies: 
Rabbit IgG-ECL  
WB: 1:10 000 (Darko, Hamburg, Germany) 
Mouse IgG-ECL 
WB: 1:10 000 (Amersham Biosciences, Freiburg, Germany) 
Rabbit IgG AlexaFlour568 
    IF: 1:500 
(Molecular Probes, Invitrogen GmbH, Darmstadt, Germany) 
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2.1.3 Used marker 
 
For the SDS-PAGE the PageRuler
TM
 Prestained Protein Ladder Plus (Fermentas GmbH, St. 
Leon-Rot, Germany) was used. This marker provide 9 bands of equal intensities in SDS-
PAGE and after Western blotting onto a PVDF membrane ranging from 11 kDa to 250 kDa. 
Therefore, it was used for high percentage (12 %) gels to detect VIP36, rhoA and flotillin-2, 
as well as for low percentage (6 %) gels to detect high molecular weight proteins (e.g. 
DPPIV, SI). 
For the lipid-analysis a standard mix of twelve different lipid components was used with a 
concentration of 200 µg / ml per lipid component. Cholesterol ester, triglycerides, oleic acid, 
cholesterol, monoacylglycerol, galactosyl cerebroside, ethanolamine, cardiolipin, serine, 
choline, and L-choline were purchased from Sigma (Taufkirchen, Germany); sphingomyelin 
were obtained from Fluka (Steinheim, Switzerland).  
 
2.1.4 Mammalian cell lines 
 
In this study the following cell lines were used: 
 
Caco-2 cells are derived from human colonic adenocarcinomas and have retained the ability 
to differentiate in culture (Zweibaum et al. 1991). They express several morphological and 
biochemical characteristics of small intestinal enterocytes (Giuliano & Wood 1991, Pinto et 
al. 1983). Similar to enterocytes, they develop an apically brush border membrane, which 
consists of uniformly organized microvilli. Several glycoproteins of the small intestine are 
endogenously expressed in Caco-2 cells, like DPPIV, SI and APN (Hauri et al. 1985, 
Zweibaum et al. 1984). 
 
Chinese hamster ovary (CHO) K1 cells are non-polarizing, fibroblastoid cells. The CHO K1 
cell line is a subclone from the original cell line, which was established from cricetulus 
griseus ovary biopsy tissue (Puck et al. 1958). 
 
CHO-Lec cells were first established by Pamela Stanley from lectin-resistant CHO cells 
(Stanley et al. 1975a). They were isolated for the resistance to the cytotoxity of plant lectins 
and are characterized by specific defects in their glycosylation. There are several cell lines 
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available with different glycosylation defects. In this study, the two mutants CHO-Lec1 
(Lec1) and CHO-Lec2 (Lec2) were used. 
 
CHO-Lec1 cells are deficient in N-acetylglucosaminyltransferase I (Stanley et al. 1975b) in 
the cis-Golgi (Fig. 2.1). Therefore, the complex N-glycosylation is not achieved and the 
Man5GlcNAc2 glycan is not further processed. However, O-glycosylation is unaffected.  
CHO-Lec2 cells lack the CMP-sialic acid transporter (Deutscher et al. 1984), which inhibits 
the last step of the N-glycosylation (Fig. 2.1). The O-glycosylation is also affected in this cell 
type. 
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Figure 2.1 N-glycan processing in the Golgi apparatus of CHO K1 and Lec cells. Terminal N-
linked glycans are present in the CHO K1 cell line (Lee et al. 2001). The defect in the Lec1 cells 
occurs in the cis-Golgi due to a defective GlcNAc-transferase I. This leads to the Man5GlcNAc2 
glycan (Chen & Stanley 2003). In the Lec2 mutant, the CMP-sialic acid transporter is lacking, which 
results into glycans without the terminal sialic acid residues (Eckhardt et al. 1998). 
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2.2 Methods 
 
2.2.1 Cell culture 
 
Caco-2 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) high glucose 
(1g/l) medium (PAA Laboratories, Pasching, Austria). CHO cells, CHO-Lec1 cells and, 
CHO-Lec2 cells were cultured in RPMI-1640 medium (PAA Laboratories, Pasching, 
Austria). 
Media was supplemented with 10 % fetal calf serum (FCS), 500,000 U / l penicillin and 10 
mg / l streptomycin (PAA Laboratories, Pasching, Austria). The cells were developed in 
tissue culture dishes (Sarstedt, Nümbrecht, Germany) at 37°C, 95 % relative humidity and 5 
% carbon dioxide atmosphere.  
When cells reach a confluence state, they were passaged. Therefore cells were washed with 
PBS and then trypsinized. When cells lost their connection to the culture dish, trypsin activity 
was stopped with culture medium (containing FCS) and cells were centrifuged for 2 min at 
850 g. After discarding the media containing trypsin they were seeded on new culture dishes.  
When cells were used for biosynthetic labelling, they were cultured for 2 to 3 h in 
methionine-free Minimum Eagle`s Medium (MEM, PAA Laboratories) supplemented with 
500,000 U / l penicillin, 10 mg / l streptomycin and, 200 mM L-glutamine. 
 
2.2.2 Establishment of stable cell lines 
 
For the establishment of stable cell lines, expressing DPPIV, CHO K1 cells, Lec1 cells and, 
Lec2 cells were transfected using FuGENE
® 
HD Transfection Reagent. FuGENE
®
 HD 
Transfection Reagent is a multi-component reagent which forms a complex with plasmid 
DNA and transports it into animal or insect cells. According to the producer’s protocol 
plasmid DNA (encoding GFP chimera of DPPIV, pEGFP-N1 vector, Takara Bio 
Europe/Clontech, Saint Germain en Laye, France) was diluted in serum-free medium to a 
concentration of 0.02 µg / µl. The transfection reagent was added in a ratio of 4:2 (reagent to 
DNA) and incubated for 5 min to achieve a complex building. The arised complex was then 
added to the cells, and incubated for 24 h. The following day, cells were passaged 1:30 as 
described above.  
For selection of the cells, the medium was supplemented with 500 µg / ml Geneticin
®
. 
Medium was changed every four days. Thereby, only cells which stably incorporated the 
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plasmid DNA into their genome, coding for Geneticin
®
-resistance are able to inactivate the 
antibiotic and survive. Positive clones were identified by confocal laser microscopy and 
Western blot analysis. 
 
2.2.3 Immunofluorescence 
 
For the characterization of the stable cell lines and for visualization of the interaction of 
DPPIV-GFP and VIP36, immunofluorescence was conducted.  
CHO K1 and Lec cells, which were stably transfected with DPPIV-GFP, were grown on 
cover slips (12 mm diameter, Roth). When they reached a confluent state, they were rinsed 
twice with PBS and then fixed with 4 % paraformaldehyd for 20 min.  
For the analysis of the stable cell lines, cells were afterwards mounted with mowiol 4-88.  
To study the interaction of DPPIV-GFP and VIP36, cells were further processed according to 
Leitner et al. (2006). The rbAb sc-67131 (H-90) (1:40) was used as a primary antibody in 
blocking buffer (0.5 % Saponin in PBS and 1 % BSA) for the detection of VIP36. As a 
secondary antibody goat anti-rabbit AlexaFlour568 (1:500) was used. After antibody 
treatment and washing procedures, cells were mounted with mowiol 4-88. As a negative 
control the same procedure was conducted by using only the secondary antibody. 
The following day, cells were visualized in the confocal laser microscope.  
 
2.2.4 Confocal laser microscopy 
 
Cells were prepared as reported previously (see 2.2.3). The fluorescence images were 
visualized using a Leica TCS SP5 microscope with an x63 oil planapochromat lens 
(numerical aperture: 1.4). Scans were made using an argon laser for the visualization of 
DPPIV-GFP (absorbance 476 nm, maximal emission 510 nm). 
Dual colour images with GFP and AlexaFluor568 were detected by sequential scans. 
AlexaFluor568 was visualized by a neon laser (absorbance 576 nm, maximal emission 599 
nm). 
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2.2.5 Western blot analysis 
 
For Western blot analysis of different proteins in Caco-2, CHO K1 and Lec cells, cells were 
lysed with 1 ml 1 % Triton X-100 in PBS with protease inhibitors and homogenized by 
trituration with a G21 needle and then maintained on ice for 1.5 h. Cells were then centrifuged 
for 10 min at 13 000 g and cell debris was discarded.  
A protein measurement was conducted according to Bradford (1976) using the Bio-Rad 
Protein Assay concentrate. The samples were processed by SDS-PAGE on 6 % or 12 % 
polyacrylamid gels (Laemmli 1970), with 50 µg of each sample loaded.  
SDS-PAGE was followed by Western blot analysis. Transfer of separated proteins to a 
Hybond-PVDF membrane (Amersham Biosciences GE Healthcare, Freiburg) was conducted 
using a tank blot for 1.5 h at 250 mA. After transfer, the membrane was blocked over night in 
5 % milk (skim milk powder in PBS) at 4°C. Immunostaining was performed with different 
primary antibodies for 45 min in 2 % milk (skim milk powder in PBS). After washing in 0.5 
% Tween 20 in PBS, anti-mouse or anti-rabbit ECL-peroxidase was used as a secondary 
antibody and incubated for 35 min. The detection was carried out with SuperSignal ELISA 
Femto Maximum Sensivity Substrate via chemilumininescence with the supersensitive 16-bit 
ChemiDoc XRS camera of a Molecular Imager
®
 (Bio-Rad Laboratories, Munich). Further 
processing of images was performed with Quantity One
®
 (Bio-Rad Laboratories, 1998). 
 
2.2.6 Immunoprecipitation 
 
Immunoprecipitation followed by Western blot analysis was conducted for the protein 
interaction experiments using Caco-2, CHO K1, and Lec cells.  
Cells were lysed as reported before (see 2.2.5). The samples were immunoprecipitated with an 
antibody directed against DPPIV, SI, APN, and LPH, depending on the experimental 
procedure, in the presence of protein A-Sepharose (Naim et al. 1991). The immunoisolates 
were further processed by SDS-PAGE on 12 % polyacrylamid gels (Laemmli 1970) followed 
by Western blot analysis. Immunostaining was performed with rbAb sc-6713 (H-90) directed 
against VIP36. For the negative control for immunoprecipitation, samples were precipitated 
with protein A-Sepharose without any antibody. 
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2.2.7 DRM extraction 
 
To investigate the association of proteins with DRMs, a discontinuous sucrose-density 
gradient was used, modifying a protocol reported by Babiychuk and Draeger in 2006.  
Cells were washed with PBS and then solubilised in PBS containing 1 % detergent (Lubrol 
WX, Triton X-100 or Tween 20) and protease inhibitors. After homogenization with a G21 
needle, cells were maintained on ice for 2.5 h. Cell lysates were then centrifuged for 10 min at 
10 000 g and cell debris was discarded. The sample was then diluted to a final concentration 
of 40 % sucrose (500 µl of the sample and 500 µl of 80 % sucrose) and layered onto an 80 % 
sucrose cushion. The 1 ml sample was then overlaid with 7 ml of 30 % sucrose followed by 1 
ml 5 % sucrose on the top (Fig. 2.2). The discontinuous sucrose-density gradient was then 
centrifuged for 18 h at 33 000 rpm (Beckman SW 40 Ti rotor) at 4°C. During centrifugation, 
the DRM-associated proteins float to the upper fractions, also called floating-fractions, of the 
gradient, whereas the non-associated proteins remain in the lower non-floating-fractions. Nine 
fractions of 1 ml each were collected from the top and analysed for protein content by 
Western blotting. The two proteins flotillin-2 and rhoA were used as controls for the DRM-
fractions and the non-DRM-fractions, respectively. 
 
5%
30%
40% 
sample
80%
Floating-fractions
Non-floating-fractions
 
Figure 2.2 Composition of the discontinuous sucrose-density gradient. The 80 % sucrose fraction 
at the bottom consists of 1 ml, as well as the sample in 40 % sucrose and the 5 % sucrose fraction on 
the top. The 30 % sucrose fraction consists of 7 ml. Floating fractions were defined as the upper three 
fractions and non-floating fractions as the lower three fractions above the 80 % sucrose cushion. 
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2.2.8 Modification of N-glycosylation 
 
To investigate the binding properties of VIP36 to glycoproteins at different stages of 
glycosylation, Caco-2 cells were treated with the glycosylation-inhibitors 1-
deoxymannojirimycin (dMM) or 1-deoxynoijrimycin (dNM). As reported previously, dMM 
hampers the α-mannosidase I in the cis-Golgi, resulting in Man8GlcNAc2 N-linked glycans. 
The inhibition of α-glucosidase I and II is achieved by treatment with dNM. Without the 
action of the glucosidases, the three glucose residues remain on the N-linked glycan which 
prevents interaction of glycoproteins with CNX and CRT. 
Caco-2 cells that were 6 days post-confluence were treated with dMM (concentration: 100 
mM) or dNM (concentration: 100 mM) for 24 h in DMEM high glucose (1g/l) medium. 
Medium containing dMM or dNM were changed once after 12 h. Cells were lysed as reported 
before (see 2.2.5). The samples were divided in three parts, one for Western blotting with 
immunostaining of VIP36 the other two were used for immunoprecipitation of DPPIV (mAb 
HBB 3/775/42) or SI (mAb HSI2). SDS-PAGE of 12 % gels (Laemmli 1970) was followed 
by Western blot analysis with immunostaining of VIP36, as reported above. 
Another experimental procedure to investigate different glycosylation stages was the use of 
the Lec cells with the defect in N-acetylglucosaminyltransferase I (Lec1) and CMP-sialic acid 
transporter (Lec2). The cell lines which were stably transfected with DPPIV-GFP were lysed 
and further processed like the treated Caco-2 cell samples. 
 
2.2.9 Pulse Chase  
 
Pulse chase experiments were conducted for the investigation of the N-glycan processing and 
maturation of DPPIV and SI. 
Caco-2 cells that were 6 days post-confluence were incubated for 2 h in methionine-free 
medium and afterwards labelled with 100 µCi [S
35
]methionine for 30 min. At time points 0, 
30, 60, 90, 120 and 240 min cells were lysed with 1 % Triton X-100 in PBS as reported above 
(see 2.2.5). The samples were divided in two and immunoprecipitated with the mAbs HBB 
3/775/42 or HSI2 directed against DPPIV or SI, respectively, in the presence of protein A-
Sepharose (Naim et al. 1991). Immunoisolates were separated on 6 % polyacrylamid gels 
(Laemmli 1970) and dried. The dried gel was incubated with a storage phosphor screen for at 
least two days. Visualization of protein bands was conducted by the phosphor imaging device 
Personal Molecular Imager FX
®
 (Bio-Rad Laboratories, Munich, Germany).  
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2.2.10 Trypsin digestion 
 
For the analysis of the folding properties of SI at different glycosylation stages, Caco-2 cells 
were treated with the two glycosylation-inhibitors dMM and dNM, which was then followed 
by a trypsin digestion. As reported above, trypsin cleaves correctly folded SI into the two 
subunits sucrase and isomaltase. 
Caco-2 cells that were 6 days post-confluence were treated with dMM or dNM 
(concentration: 100 mM) for 3 h concomitant with incubation in methionine-free medium. 
The medium containing dMM or dNM was changed once after 1.5 h. Afterwards cells were 
labelled with 100 µCi [S
35
]methionine for 4 h in the presence of dMM or dNM 
(concentration: 100 mM), followed by lysis with 1 % Triton X-100 in PBS. The samples were 
maintained on ice for 2 hours. Afterwards, samples were immunoprecipitated with mAbs 
HSI2 and HBB 3/705/60 directed against SI in the presence of protein A-Sepharose (Naim et 
al. 1991). The immunoisolates were then incubated with 500 µg trypsin for 1 h at 37°C. The 
trypsin-digested samples were further processed by SDS-PAGE on 6 % polyacrylamid gels 
(Laemmli 1970), dried, and the incubated phosphor screen was analyzed by the phosphor 
imaging device Personal Molecular Imager FX
®
.  
 
2.2.11 Co-immunoprecipitation 
 
The co-immunoprecipitation experiment preceded by pulse chase experiment was used to 
investigate the binding of VIP36 to DPPIV and SI in dependence of N-glycosylation 
processing and maturation of these proteins. 
Caco-2 cells that were 6 days post-confluence were cultured for 2 h in methionine-free 
medium and then labelled with 100 µCi [S
35
]methionine for 30 min. At time points 0, 30, 60, 
90, 120, and 240 min cells were lysed with 1 % Triton X-100 in PBS as reported before (see 
2.2.5). For the following immunoprecipitation samples were divided in two and incubated 
with the mAbs HBB 3/775/42 or HSI2 directed against DPPIV or SI, respectively, in the 
presence of protein A-Sepharose (Naim et al. 1991). The immunoisolates were then incubated 
with 0.5 % SDS in PBS for 1 h at 37°C. With this step, the connection between SI or DPPIV 
and VIP36 as well as protein A-Sepharose was destroyed. Afterwards, cells were centrifuged 
and the supernatant was again immunoprecipitated. The rbAb sc-67131 (H-90) against VIP36 
was used in the presence of protein A-Sepharose (Naim et al. 1991). Therefore only the 
VIP36 molecules which bound to either DPPIV or SI are precipitated. Immunoisolates were 
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further processed by SDS-PAGE on 12 % polyacrylamid gels (Laemmli 1970), dried and the 
incubated phosphor screen was analyzed by the phosphor imaging device Personal Molecular 
Imager FX
®
.  
 
2.2.12 Lipid-analysis of DRMs 
 
To determine if there are significant differences in the lipid composition of the different 
DRM-types between CHO K1 and the two Lec cell lines, a lipid-analysis was performed. 
For the lipid-analysis, CHO K1, Lec1, and Lec2 cells were used. Three confluent culture 
dishes of each cell line were lysed with 1 % detergent (Triton X-100, Tween 20 or Lubrol 
WX) in PBS and maintained on ice for 2.5 h. After centrifugation at 10 000 g for 10 min cell 
debris was discarded and the samples were centrifuged for 1.5 h at 100 000 g in a Ti 100 rotor 
(Beckman). During centrifugation, the DRMs are separated from the rest of the cell lysate and 
can be found as a pellet at the bottom of the centrifuge tube. After centrifugation, the 
supernatant was discarded. The pellet was washed three times in 1 ml PBS and one time in 1 
ml H2O for 10 min at 1900 g to get rid of the remaining detergent. Samples were then diluted 
in 1 ml PBS and used for the lipid extraction.  
The lipid extraction was performed following Bligh and Dyer (1959). For analysis of lipid 
components, samples were dried at room temperature and then resolved in chloroform / 
methanol (2:1 volume).  
Samples were isolated on thin layer chromatography (TLC) (glass, SI-60, Phenomenex) 
according to a protocol from the IBM Jena (Quantitative Lipidanalyse biologischer Proben 
durch hochauflösende Dünnschichtchromatographie). The TLC was processed in a glass 
chamber. The plate was then dried and stained with copper sulphate solution and developed at 
110°C.  
Dried TCL plates were analysed using the software “ImageJ 1.41i” and “Microsoft Office 
Exel 2003”.  
 
All performed experiments were repeated at least three times. One representative figure is 
shown for every experiment in the results. 
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2.2.13 Statistical analysis 
 
For the analysis of the lipid composition in the different DRM fractions for the CHO K1 and 
Lec cells the values of eight samples were used for each cell line per lipid component and 
DRM extraction.  
First, it was tested if the values have a normal distribution. Since this was not confirmed, the 
Mann-Whitney U test was used.  
The Mann-Whitney U test is a method to determine whether two independent variables have 
equally large values (Mann & Whitney 1947). It is a two tailed, non-parametric analysis, 
based on the rank of the values of both variables.  
In this study, it was used to test for significant difference between the amount of the different 
lipids in µg for CHO K1 and the two different Lec cells. The working hypothesis was defined 
as H0: ValuesCHO = ValuesLec1 or ValuesCHO = ValuesLec2 for the different lipid components. 
The hypothesis was rejected if p-value was ≤ 0.05. All statistical analysis were conducted 
using the program SPSS (version 18, PSAW, IBM Deutschland GmbH, Munich, Germany). 
The significant threshold was 5 % for all analyses. 
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3. Results 
 
 
3.1 Characterization of the stable transfected CHO cell lines 
 
In order to analyze the binding of VIP36 to DPPIV under glycosylation-deficient conditions, 
Lec1 and Lec2 cells, which both have been shown to exhibit glycosylation defects, were 
stably transfected with DPPIV-GFP using FuGENE
® 
HD Transfection Reagent. The stable 
cell lines were used to investigate the interaction of DPPIV with VIP36 when later steps of 
the N-glycosylation beyond the cis-Golgi were inhibited. The CHO K1 cells without 
glycosylation defects were used as a control.  
A verification of correct expression, intracellular localization and transport competence of 
DPPIV-GFP was performed by confocal laser microscopy and Western blot analysis. 
For the confocal analysis cells were grown on coverslips, fixed and then mounted with 
mowiol 4-88. Figure 3.1 shows the expression of DPPIV-GFP in the three cell lines in a 
steady state situation. The images show that the transfection was successful for all three cell 
lines since there are many cells which could be detected by the argon laser, visualizing 
DPPIV-GFP, which is shown in green colour. However, the transfection rate is not equal in 
the cell lines. As shown in Figure 3.1 the transfection rate is higher in the Lec cells, visualized 
by the stronger signal. DPPIV-GFP is expressed to a great extend at the cell surface and also 
in intracellular compartments in all three cell lines. The data show that DPPIV-GFP is 
transported to the cell surface even when the glycosylation is not complete. 
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Figure 3.1 Confocal images of the DPPIV-GFP stable cell lines. CHO K1, Lec1, and Lec2 were 
stably transfected with DPPIV-GFP using FuGENE
® 
HD Transfection Reagent. The left image shows 
the fixed CHO K1 cells, the image in the middle Lec1 cells and the right image Lec2 cells. The white 
arrows mark DPPIV-GFP at the cell surface and the arrows in yellow point out intracellularly 
distributed DPPIV-GFP in the cells. 
 
For the Western blot analysis cells were lysed and 50 µg protein amount, measured by protein 
assay, were loaded on SDS-PAGE. Immunostaining was conducted using the mAb HBB 
3/775/4 directed against DPPIV.  
Western blot analysis obtained a protein band corresponding to DPPIV-GFP that can be 
detected for all three cell lines (Fig. 3.2). However, the size of the protein bands differs in the 
cell lines. The CHO K1 cell line expresses complex glycosylated DPPIV-GFP with the 
predicted size of ~137 kDa, consisting of the 110 kDa DPPIV and the 27 kDa GFP (Fig. 3.2, 
lane 1). The protein band for the Lec1 cell line is lower in comparison to the control band 
(Fig. 3.2, lane 2). This is a result of the defective glycan processing in the Lec1 mutant, where 
the N-acetylglucosaminyltransferase I is lacking and therefore the Man5GlcNAc2 is no further 
processed (Fig. 3.2, lane 2). The size of the protein band in the Lec2 mutant is only slightly 
lower in comparison to the control. In this case the lack of CMP-sialic acid transporter leads 
to the missing sialic acid as a final carbohydrate residue on N-linked glycans in this cell line 
(Fig. 3.2, lane 3).  
The amount of DPPIV also differs between the three cell lines. DPPIV-GFP is expressed to a 
lesser extend in the control cell line in comparison to the Lec cells, where stronger protein 
bands are detectable for DPPIV-GFP when loading the same protein amount for every cell 
line (Fig. 3.2). This finding is in agreement with the confocal data. 
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Figure 3.2 Western blot analysis of DPPIV-GFP in CHO K1, Lec1, and Lec2 cells. 
Immunostaining was conducted with mAb HBB 3/775/42 directed against DPPIV. The first lane 
represents CHO K1 with the highest molecular weight of ~137 kDa. Lane 2 shows the protein band 
for DPPIV-GFP in Lec1 cells with a lower molecular weight. DPPIV-GFP expressed in Lec2 cells is 
shown in lane three with a slightly lower molecular weight in comparison to CHO K1 cells. The 
different terminal glycoforms which are expressed in the cell lines are shown below the corresponding 
protein band. 
 
However, taken together the results show that DPPIV-GFP is expressed in all three cell lines. 
The confocal data obtained that DPPIV-GFP achieves a normal transport competence in all 
three cell lines, irrespectively of glycosylation defect (Fig. 3.1). The Western blot analysis 
verify the predicted glycosylation defects of Lec1 and Lec2 cells based on the smaller size of 
the expressed protein DPPIV-GFP (Fig. 3.2, lane 2 and 3). Therefore, this cell model can be 
used for further experiments concerning the interaction of DPPIV-GFP with VIP36. 
 
 
3.2 VIP36 is expressed in different cell lines 
 
To analyze the defined aims of this study concerning VIP36, different VIP36-expressing cell 
lines were used. It is known from other studies, that VIP36 is expressed in many different cell 
lines e.g. MDCK cells, NIH 3T3 fibroblasts, rat parotid acinar cells, and GH3 cells (Fiedler et 
al. 1994, Fiedler & Simons 1995, Shimada et al. 2003a, Shimada et al. 2003b). The cell lines 
that were used in this study were Caco-2 cells, CHO K1 cells, Lec1 cells, and Lec2 cells. 
To confirm the expression of VIP36 in the used cell lines Western blot analysis were 
conducted. For the experiment cells were lysed and 50 µg protein amount, measured by 
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protein assay, were separated on SDS-PAGE. Immunostaining was conducted by using the 
rbAb sc-67131 (H-90) directed against VIP36.  
The result showed a clear protein band at the predicted size of 36 kDa in all tested cell lines 
(Fig. 3.3). In Lec1 and Lec2 cells, a slightly lower band appeared. This is a result of the 
incomplete glycan processing at the single N-glycosylation site of VIP36, since it is known 
that this N-glycosylation site is normally complex glycosylated (Füllekrug et al. 1999). The 
protein band for Caco-2 cells appeared almost at the same height than in the CHO K1 cell 
line.  
With this experiment, I could show that VIP36 is expressed endogenously in the tested cell 
lines. Therefore, all selected cell types can be used for the examination of interaction with 
glycoproteins and DRM-association of VIP36. 
 
VIP36
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Figure 3.3 VIP36 expressed in different cell lines. Caco-2 cells, CHO K1, Lec1, and Lec2 cells were 
lysed and preceded by SDS-PAGE. Western blot analysis were conducted using rbAb sc-67131 (H-90) 
directed against VIP36. The image shows protein bands at the height of 36 kDa, corresponding to 
VIP36 for the four cell lines 
 
 
3.3 Interaction of VIP36 with glycoproteins in Caco-2 cells 
 
Since it is known that VIP36 is interacting with different glycoproteins like custerin, α-
amylase and α-1-antitrypsin (Hara-Kuge et al. 2002, Hara-Kuge et al. 2004, Reiterer et al. 
2010), I was searching for further interaction partners of VIP36.  
In the past it has been shown that VIP36 recognize more apical than basolateral sorted 
glycoproteins (Hara-Kuge et al. 2002), and that it bind to membrane proteins (Hara-Kuge et 
al. 1999). Therefore, I focused on highly glycosylated transmembrane proteins which are 
apically sorted.  
Caco-2 cell lysates were used to immunoprecipitate the glycoproteins DPPIV, SI, LPH and 
APN, which are all N- and O-glycosylated transmembrane proteins. One lysate was treated 
with protein A-Sepharose alone, to proof that protein bands which will appear when VIP36 
was binding to one of the immunoprecipitated glycoproteins were not due to an unspecific 
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binding of the VIP36 antibody to protein A-Sepharose. This procedure was followed by 
Western blot analysis with rbAb sc-67131 (H-90) directed against VIP36.  
Figure 3.4 shows the Western blot analysis of the immunoprecipitation experiment. The first 
lane shows the negative control, were only protein A-Sepharose was added to the lysate 
without a specific antibody. Here, no band can be detected. The immunoprecipitated samples 
are shown in lanes 2 to 5. A band corresponding to VIP36 was detected for the two 
immunoprecipitated glycoproteins SI (Fig 3.4, lane 2) and DPPIV (Fig. 3.4, lane 3), but no 
band could be detected for APN and LPH (Fig. 3.4, lanes 4 and 5). This experiment reveals 
that VIP36 is precipitated together with the two glycoproteins SI and DPPIV. Due to the 
intensity of the bands, VIP36 might bind more DPPIV proteins than SI proteins.  
 
 
Figure 3.4 Interaction of VIP36 with glycoproteins in Caco-2 cells. Cells were lysed and 
immunoprecipitated with mAbs directed against SI, DPPIV, APN or LPH. One sample was treated 
with protein A-Sepharose without any antibody as a negative control. Immunoisolates were further 
processed by Western blot analysis with rbAb directed against VIP36. The experiment revealed a faint 
band for the binding of SI and a strong band for binding of DPPIV. No band can be detected for the 
negative control and the immunoprecipitated proteins APN and LPH. 
 
This experiment was repeated for the proteins DPPIV and SI to proof if there is a difference 
in binding of VIP36 to DPPIV and SI. As a reference for protein amount of VIP36, DPPIV, 
and SI, 50 µg of Caco-2 cell lysate was loaded on SDS-PAGE. 
The results show a clear band detectable for VIP36 in the lysate (Fig. 3.5a, lane 1). The 
amount of VIP36 which binds to DPPIV is larger than in the lysate (Fig. 3.5a, lane 2) and the 
band intensity for VIP36 which binds to SI is weaker (Fig. 3.5a, lane 3). However, when the 
protein bands for DPPIV and SI were compared in Fig. 3.5b, it is shown that there is a much 
greater amount of DPPIV in 50 µg of the lysate detectible than for SI. This indicates that the 
stronger binding of VIP36 is due to the greater amount of DPPIV in Caco-2 cells. 
With these experiments I could identify DPPIV and SI as new interaction partners of VIP36.  
VIP36 binds different amounts of DPPIV and SI, which might be due to the greater protein 
amount of DPPIV in the cell lysates. 
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Figure 3.5 Interaction of VIP36 with DPPIV and SI in Caco-2 cells. a: Cells were lysed and 
immunoprecipitated with mAbs directed against DPPIV or SI or directly loaded on SDS-PAGE. 
Western blot analysis showed a protein band for VIP36 in the lysate of Caco-2 cells. The second and 
third lanes represent VIP36 isolated by immunoprecipitation of DPPIV and SI, respectively. b: Cell 
lysates were processed on SDS-PAGE followed by Western blotting with immunostaining of DPPIV 
and SI. 
 
 
3.4 Interaction of VIP36 with DPPIV under glycosylation-deficient conditions 
 
For the investigation of interaction between VIP36 and DPPIV under glycosylation-deficient 
conditions, the CHO K1 cells and Lec cells, which were stably transfected with DPPIV-GFP, 
were used. Therefore, Western blot analysis (processed as in 3.2) as well as confocal laser 
microscopy was conducted. Figure 3.6 shows the Western blot analysis of the three different 
cell lines. A specific protein band which corresponds to VIP36 can be visualized. This 
experiment revealed an interaction of VIP36 with DPPIV-GFP in the control cells and also in 
the glycosylation-deficient cells. However, the binding properties of VIP36 to DPPIV in the 
glycosylation-defective cell lines differ in comparison to the CHO control cells. For Lec1 and 
Lec2 cells I obtained an increased binding, represented by the stronger protein band for Lec1 
and Lec2 cells (Fig. 3.6). However, this increased binding is possibly caused by the higher 
expression level in the Lec cells as it was shown in chapter 3.1. 
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Figure 3.6 Interaction of VIP36 with DPPIV-GFP in CHO K1 and Lec cells. CHO K1 and Lec 
cells were lysed and DPPIV was immunoprecipitated followed by Western blot analysis with 
immunostaining of VIP36. Lane 1-3 represent the protein band for VIP36, interacting with DPPIV-
GFP in the three cell lines CHO K1, Lec1, and Lec2. 
 
The interaction of VIP36 with DPPIV could also be confirmed by confocal laser microscopy. 
Therefore, the CHO K1 cells and Lec cells which are stably transfected with DPPIV-GFP 
were used to visualise VIP36 by immunofluorescense microscopy. For detection of the 
endogenous VIP36 the rbAb sc-67131 (H90) was used followed by immunostaining with 
AlexaFlour568 as a secondary antibody, which labelled the protein in red. 
Figure 3.7 showed that there are a few colocalization spots of VIP36 and DPPIV, which 
appeared in yellow, in the different cell lines. The single channel pictures for DPPIV-GFP 
showed a staining of the cell surface and intracellular compartments (Fig. 3.7a-c, DPPIV-
GFP) in all three cell lines as it was already shown in Fig. 3.1. VIP36 is localized 
intracellularly and no cell surface staining can be observed in the three cell lines (Fig. 3.7 a-c, 
VIP36-AlexaFlour568). 
The control cell line displayed colocalization of the two proteins which appear intracellularly 
(Fig. 3.7a, merge). Some of these interactions seem to be near the cell surface, the other in the 
region of the Golgi.  
The colocalization for Lec1 is shown in figure 3.7b (merge). Here, the colocalizations which 
can be detected are localized intracellularly, near the cell surface. 
The colocalization of VIP36 and DPPIV-GFP in Lec2 cells is also intracellularly, in the Golgi 
region (Fig.3.7c, merge). Here no interaction near the cell surface was observed. 
 
In conclusion, the above mentioned interaction studies for DPPIV-GFP and VIP36 in CHO 
K1 and Lec cells showed that VIP36 is binding to this glycoproteins also when the 
glycosylation is inhibited at a later step along the secretory pathway, beyond the cis-Golgi.  
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Figure 3.7 Colocalization of VIP36 and DPPIV-GFP in CHO K1 and Lec cells. The stably 
transfected cells were labelled with anti-VIP36 Ab followed by treatment with AlexaFlour568 as a 
second antibody. DPPIV-GFP appeared in green, VIP36 in red. Merge visualize the overlay of both 
laser channels and show colocalizations, which are marked by white arrows, appearing in yellow. a: 
CHO K1, b: Lec1, c: Lec2. 
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3.5 Binding properties of VIP36 during glycoprotein maturation 
 
As a next step, the transport kinetics of DPPIV and SI as well as the binding of VIP36 to these 
two proteins was examined by pulse chase experiments.  
To investigate if there is a change in the binding of VIP36 to DPPIV and SI over time, Caco-2 
cells were labelled with [
35
S]methionine for 30 min followed by different chase time points. 
Afterwards an immunoprecipitation with the mAbs HBB 3/775/42 or HSI2 directed against 
DPPIV or SI, respectively, was performed. One sample of each time point was then further 
processed by SDS-PAGE on 6 % gels to show the maturation and the glycosylation stage of 
DPPIV and SI over time. The other part of each sample was then treated with 0.5 % SDS at 
37°C for 1 h to destroy the binding of DPPIV or SI to VIP36 and protein A-Sepharose. This 
was followed by immunoprecipitation of VIP36, to only isolate VIP36 molecules which bind 
to DPPIV and SI at the certain time points, followed by SDS-PAGE on 12 % gels. 
The pulse chase experiment for DPPIV showed a strong band at 100 kDa at time point 0 min, 
corresponding to its mannose-rich form (DPPIVh, Fig. 3.8, lane 1). After 30 min of chase, 
there is a second band at 124 kDa which correspond to the complex form of this protein 
(DPPIVc, Fig. 3.8, lane 2). The mannose-rich form is weaker in comparison to the preceding 
time point. At time point 60 min the mannose-rich form is again weaker and the complex 
band gets stronger (Fig. 3.8, lane 3). From time point 90 min the mannose-rich form could not 
be detected and DPPIV appeared only complex glycosylated (Fig. 3.8, lane 3-5).  
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Figure 3.8 Maturation of DPPIV. Caco-2 cells were biosynthetically labelled for 30 min and then 
lysed at the six different time points. Samples were immunoprecipitated with mouse anti-DPPIV 
antibody. The figure shows protein maturation of DPPIV. The bands were detected at the size of 100 
kDa for mannose-rich DPPIV and 124 kDa for complex glycosylated DPPIV. 
 
For SI, a very faint protein band at 210 kDa, which correspond to the mannose-rich form, 
could be detected at time point 0 min (pro-SIh, Fig. 3.9, lane 1). The following time point (30 
min) this 210 kDa band appeared stronger (Fig. 3.9, lane 2). At time point 60 min the pro-SIh 
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band again become stronger and a second weaker band appeared at 245 kDa, indicating the 
complex form of SI (pro-SIc, Fig. 3.9, lane 3). The next time point (90 min), pro-SIh appears 
slightly weaker than the proceeding, whereas pro-SIc band grows stronger (Fig. 3.9, lane 4). 
There are almost equal band intensities for pro-SIh and pro-SIc at time point 120 min (Fig. 3.9, 
lane 5). This corresponds into a slightly reduction of pro-SIh and an increase of pro-SIc. At the 
last time point (240 min) only pro-SIc could be detected, indicating that the labelled pro-SI is 
fully matured. 
The results show that DPPIV reaches its complex glycosylated form earlier than SI, which is 
in agreement with already published data (Hauri et al. 1985). 
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Figure 3.9 Maturation of SI. Caco-2 cells were biosynthetically labelled for 30 min and then lysed at 
the six different time points. Samples were immunoprecipitated with HSI2 antibody. The figure shows 
protein maturation of SI. The bands were detected at the size of 210 kDa for mannose-rich SI and 245 
kDa for complex glycosylated SI. 
 
The co-immunoprecipitation experiment showed that VIP36 binds to DPPIV at the first time 
points. As shown in Fig. 3.10, a band at 36 kDa is shown in the first four lanes which 
correspond to VIP36. Therefore, VIP36 can be detected at the first four time points 0, 30, 60, 
and 90 min with an increasing binding, reaching its maximum at 90 min of chase. This 
corresponds to a binding of VIP36 to DPPIV when the mannose-rich form (DPPIVh) is 
existent at the first two time points and also at the later time points (60 and 90 min) when 
DPPIV is complex glycosylated (Fig. 3.8). 
The binding of VIP36 to SI appeared at different time points. At time points 0 and 30 min, 
VIP36 binds to SI (Fig. 3.10, lane 1-3). Therefore, VIP36 binds when pro-SIh is existent (Fig. 
3.9). However, at the following time point (60 min) VIP36 can not be detected (Fig 3.10, lane 
3), indicating that the association of the two proteins untie. After 90 min of chase, there is 
again a binding between VIP36 and SI since there is a band detectable in lane 4 (Fig. 3.10). 
This binding gets stronger, due to a stronger band at time point 120 min (Fig. 3.10, lane 5), 
which is the strongest band corresponding to the strongest binding between VIP36 and its 
cargo. The association again unties and can no longer be observed at the last time point (Fig 
3.10, lane 6) when there is only complex glycosylated SI detectable (Fig. 3.9). 
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Figure 3.10 Binding of VIP36 to the glycoproteins DPPIV and SI during protein maturation. 
Caco-2 cells were biosynthetically labelled for 30 min and then lysed at the six different time points. 
Samples were immunoprecipitated with anti-DPPIV or anti-SI and then treated with 0.5 % SDS for 1 h 
at 37°C. A second immunoprecipitation was conducted using anti-VIP36 antibody. 
 
These results suggests an interaction of VIP36 with these two proteins at an early stage of 
development in the ER/ERGIC when the protein has left the CNX/CRT cycle and also later in 
the Golgi or TGN for both proteins.  
 
 
3.6 Influence of N-glycosylation on VIP36 binding properties 
 
To examine if binding of VIP36 is influenced when N-glycosylation is inhibited in the early 
steps of protein transport, the glycosylation inhibitors 1-deoxynojirimycin (dNM) and 1-
deoxymannojirimycin (dMM) were used. Treatment with dNM modulates the N-
glycosylation since it inhibits α-glucosidase I and II in the ER, which prevents binding of 
CNX and CRT. For the modulation of complex glycosylation, dMM was used which inhibits 
α-mannosidase I in the cis-Golgi, resulting into Man8GlcNAc2 glycans.  
Caco-2 cells were treated either with dNM or dMM for 24h with a change of the medium 
after 12h. Afterwards, an immunoprecipitation of DPPIV and SI was performed, followed by 
Western blotting with anti-VIP36 Ab.  
The results show that the amount of VIP36 in the treated cells is reduced for both treatments 
(Fig. 3.11a). For the dMM treatment a reduction of VIP36 expression of 16.5 % can be 
observed (Fig. 3.11b). The dNM treatment causes a reduction of 23 % of VIP36 expression 
(Fig. 3.11b). 
Comparison of the amount of VIP36 which binds to DPPIV in the treated and non-treated 
cells revealed a reduction of 39.3 % and 38.5 % for the dMM and dNM treatments, 
respectively (Fig. 3.11a and b, lanes 4-6). This shows that VIP36 might not bind to all DPPIV 
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proteins which are synthesized when only early glycosylation forms are present, since it might 
also bind to complex glycosylated proteins (Fig. 3.10). 
By comparing the amount of VIP36 which binds to SI, a bigger difference between the two 
treatments could be detected. The treatment with dMM results in a reduction of 36.8 % in 
comparison to untreated cells, which is the least observed reduction (Fig. 3.11a and b, lane 8). 
However, there is a strong decrease of binding to SI in the dNM-treated cells (Fig. 3.11a, lane 
9). This reduction was identified as 64.7 % (Fig. 3.11 b). This indicates a requirement of the 
first N-glycosylation processing steps for a proper binding of VIP36 to SI. 
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Figure 3.11 Inhibition of N-glycosylation. a: Caco-2 cells were treated with dMM or dNM for 24 h. 
The first three lanes show Western blot analysis with immunostaining of VIP36 of the cell lysates 
without and with dMM or dNM treatment. The following three lines represent the Western blot 
analysis of VIP36 after IP with HBB 3/775/42 directed against DPPIV again without and with dMM 
or dNM treatment. The same procedure was conducted for SI using mAb HSI2, which is shown in the 
last three lanes. b: The quantification of the band intensities was conducted for the lysates and the IP 
for DPPIV and SI. The untreated sample was set as 100 % (x-axis) in comparison to the treated 
samples (y-axis). c: control, m: dMM treatment, n: dNM treatment, d: IP DPPIV, s: IP SI. 
 
To investigate the binding properties when later steps of N-glycosylation are inhibited, 
DPPIV was stably transfected into Lec1 and Lec2 cells (see chapter 3.1). As already reported, 
immunoprecipitation experiments revealed that the binding of VIP36 to DPPIV increases in 
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the Lec cells (Fig. 3.6). However, this increased binding could be a result of the different 
expression levels in the different cell lines, as was shown in Fig. 3.1 and Fig. 3.2. 
 
 
3.7 Influence of N-glycosylation on SI folding 
 
In the previous section, it was shown that there is a strong reduction of the binding between 
VIP36 and SI, when N-glycosylation is hampered by dNM treatment, and a moderate 
reduction for the dMM treatment. Therefore, the question arises if VIP36 might bind to SI to a 
lesser extent because of its incorrect folding, which might be caused by incomplete 
glycosylation due to the treatments. To reconsider this assumption, Caco-2 cells were treated 
with trypsin. It is known that SI is digested by trypsin into the two subunits sucrase and 
isomaltase (Hauri et al. 1985, Naim et al. 1988b). When SI is not folded correctly, the protein 
subunits are trypsin-sensitive and will be degraded. 
Caco-2 cells were treated with 100 mM dMM or dNM in the presence of methionine-free 
medium for 3 h followed by biosynthetic labelling with additional dMM or dNM treatment 
for 4 h. Then samples were immunoprecipitated with two antibodies detecting SI. HSI2 
detects the sucrase subunit of SI, whereas the HBB 3/705/60 detects early stages and partially 
folded SI molecules (Hauri et al. 1985, Beaulieu et al. 1989). The immunoisolates were then 
treated with 500 µg trypsin for 1 h at 37°C and processed on 6 % SDS-PAGE. 
The results show that the trypsin digestion worked for the three samples but not the whole 
amount of SI molecules were digested (Fig. 3.12). 
In Figure 3.12, the control pattern is shown in the first lane. The upper bands at 210 and 245 
kDa represent pro-SIh and pro-SIc, respectively. Part of SI is cleaved by trypsin into sucrase 
and isomaltase. The bands which are at the predicted size of 145 kDa for isomaltase and 130 
kDa for sucrase are blurred. This is a result of the digestion, which leads also into a separation 
on the SDS gel of complex and mannose-rich sucrase and isomaltase.  
The second lane shows the dMM treated SI. The upper band corresponds to pro-SIh. 
However, no band at the size of 245 kDa, corresponding to pro-SIc could be detected. 
Therefore the dMM treatment completely hampered mannosidase I in the Golgi. The trypsin 
digestion showed that there are two bands, which represents the mannose-rich form of sucrase 
and isomaltase.  
The third lane shows the dNM treatment. For this treatment, SI showed a strong mannose-rich 
band as well as a weaker complex form. This pattern revealed that the dNM treatment, which 
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hampered the α-glucosidase I and II in the ER, was not completely successful. After trypsin 
digestion, there is a strong band at 130 kDa which corresponds to the sucrase subunit. The 
second band at 145 kDa corresponds to the isomaltase subunit and is again blurred due to 
separation of complex and mannose-rich forms of sucrase and isomaltase.  
This results show that SI is correctly folded when treated with dMM or dNM and is therefore 
digested into the two subunits sucrase and isomaltase by trypsin. 
 
 
Figure 3.12 Trypsin digestion of SI. Caco-2 cells were biosynthetically labelled for 4 h concomitant 
with dMM or dNM treatment. Samples were immunoprecipitated with mAbs HSI2 and HBB 3/705/60 
directed against SI. Immunoisolates were then incubated with trypsin. SI is cleaved into the two 
subunits sucrase and isomaltase. The upper bands represent uncleaved mannose-rich (210 kDa) and 
complex (245 kDa) SI. The lower bands are the result of trypsin digestion and show the separated 
subunits sucrase (130 kDa) and isomaltase (145 kDa).  
 
 
3.8 DRM-association of VIP36 and interaction with glycoproteins 
 
Association with DRMs plays a crucial role for the trafficking, sorting and function of the two 
glycoproteins DPPIV and SI. It is known that they associate with late (extracted with Triton 
X-100 or Lubrol WX) and early DRMs (extracted with Tween 20) along the secretory 
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pathway (Alfalah et al. 2002, Jacob et al. 2003, Alfalah et al. 2005). Since VIP36 was first 
isolated from CHAPS DRMs (Fiedler et al. 1994) and is interacting with DPPIV and SI, 
which was discovered in the previous experiments, the question arises if VIP36 is also 
associated with other types of DRMs, and further, if there is an interaction with cargo in 
DRMs. 
For the investigation of DRM-association of VIP36, Caco-2 cells were lysed with 1 % of one 
of the three non-ionic detergents Triton X-100, Lubrol WX, or Tween 20, followed by a 
discontinuous sucrose-density gradient centrifugation. Nine fractions, ranging from 5 % to 40 
% sucrose, were collected and analysed by Western blotting with immunostaining of VIP36. 
The two proteins flotillin-2 and rohA were used as controls for the DRM-fractions and the 
non-DRM-fractions, respectively. The DRM-fractions were expected in the three first 
fractions of the gradient, whereas the non-DRM-fractions remain at the bottom of the gradient 
in the three lower fractions (above the 80 % sucrose cushion). 
When DRMs were extracted with Triton X-100, the discontinuous sucrose-density gradient 
pattern shows that VIP36 is not found in the floating-fractions of the gradient. Figure 3.13 
(line 1) shows that protein bands for VIP36 are only detected in the non-floating-fractions 7 
and 8. This pattern could also been shown for DRMs extracted with Lubrol WX (Fig. 3.13, 
line 4), where protein bands which correspond to VIP36 appeared in the fractions 8 and 9. 
However, the extraction of Tween 20 DRMs displays an association of VIP36 with these 
microdomains, since there are strong protein bands detected in the floating-fractions 1 and 2 
(Fig. 3.13, line 7). Therefore, VIP36 is associated with these types of microdomains, which 
can be found early in the secretory pathway. 
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Figure 3.13 DRM-association of VIP36 in Caco-2 cells. Caco-2 cell lysates were processed by 
sucrose-density gradients. Nine fractions were collected from the top, ranging from 5 % sucrose in the 
upper fraction to 40 % sucrose in the lowest fraction. The figure shows the DRM extraction with 
Triton X-100, Lubrol WX, and Tween 20 followed by Western blotting with immunostaining of 
VIP36, flotillin-2, and rhoA. Flotillin-2 and rhoA are controls for the DRM-fractions and the non-
DRM-fractions, respectively. 
 
The extraction of Tween 20 DRMs from Caco-2 cells reveals that DPPIV and SI are 
transported into these microdomains, like VIP36 (Fig. 3.14) and can be found in the DRM-
fractions of the gradient. This association with early DRMs along the secretory pathway was 
already reported for these two proteins (Alfalah et al. 2005). 
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Figure 3.14 Association of DPPIV and SI with Tween 20 DRMs. Caco-2 cells were lysed with 
Tween 20 and a discontinuous sucrose-density gradient was performed. Nine fractions were collected 
from the top, ranging from 5 % sucrose in the upper fraction to 40 % sucrose in the lowest fraction. 
The figure shows the DRM extraction with Tween 20 followed by Western blotting with 
immunostaining of DPPIV, SI, flotillin-2, and rhoA. Flotillin-2 and rhoA are controls for the DRM-
fractions and the non-DRM-fractions, respectively. 
 
The localization of two proteins in the same type of DRMs does not automatically imply that 
they are interacting in these membrane microdomains. Thus, to test if VIP36 is interacting 
with DPPIV and SI in Tween 20 DRMs immunoprecipitation with antibodies directed against 
DPPIV and SI of the nine fractions of the sucrose-density gradient followed by Western blot 
analysis with immunostaining of VIP36 was performed.  
This experiment displays an interaction of VIP36 with DPPIV and SI in Tween 20 DRMs, 
shown by protein bands appearing in the first three fractions of the sucrose-density gradient 
(Fig.3.15). 
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Figure 3.15 Interaction of VIP36 with DPPIV and SI in Tween 20 DRMs. Caco-2 cells were lysed 
with Tween 20 and a discontinuous sucrose-density gradient was performed. Nine fractions were 
collected and immunoprecipitated with mAbs directed against DPPIV or SI. This procedure was 
followed by Western blot analysis with immunostaining of VIP36. 
 
 
3.9 DRM-association of VIP36 and DPPIV under glycosylation-deficient       
conditions 
 
Recruiting into DRMs is known to be dependent on glycosylation of certain proteins. For 
DPPIV efficient association with DRMs requires N- and O-glycosylation (Alfalah et al. 
2002). Therefore, it was interesting to find out if VIP36 or the interacting glycoprotein DPPIV 
are transported into DRMs when there is an incomplete glycosylation, like in Lec1 and Lec2 
cells.  
For the investigation of DRM-association of VIP36 and DPPIV-GFP, CHO K1 cells, Lec1 
cells, and Lec2 cells were treated as reported in chapter 3.8. For the Western blot analysis the 
antibodies directed against DPPIV, VIP36, flotillin-2 and rhoA were employed. 
The extraction of Triton X-100 DRMs shows a similar distribution of VIP36 and DPPIV in 
CHO K1 and Lec cells. Like in Caco-2 cells, VIP36 can be detected in the non-DRM-
fractions (Fig. 3.16, fraction 7-9) in all three cell lines. DPPIV is transported into the DRM-
fractions of the gradient, irrespectively of glycosylation stage. The main protein amount is 
detected in the first three fractions of the gradient, but there are also faint protein bands in the 
fractions 4 to 8 for the control and Lec2 cells (Fig. 3.16, line 2 and 10). The distribution of 
DPPIV in the Lec1 cells is restricted to fractions 1 and 2, as well as fractions 6 and 7 (Fig. 
3.16, line 6). Flotillin-2 and rhoA are normally distributed in all three cell lines, so that the 
DRMs seem to be still existent when glycosylation is incomplete in the cell (Fig, 3.16). 
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Figure 3.16 Extraction of Triton X-100 DRMs of CHO K1, Lec1, and Lec2 cells. CHO K1, Lec1, 
and Lec2 cells were lysed with Triton X-100 followed by a discontinuous sucrose-density gradient. 
Nine fractions were collected from the top, ranging from 5 % sucrose in the upper fraction to 40 % 
sucrose in the lowest fraction. Western blotting analysis with immunostaining of VIP36, DPPIV, 
flotillin-2, and rhoA was performed. Flotillin-2 and rhoA are controls for the DRM-fractions and the 
non-DRM-fractions, respectively. 
 
In Caco-2 cells, an association with Tween 20 DRMs could be shown (Fig. 3.13). When 
DRM extraction with this detergent was conducted using the CHO K1 and Lec cells, a 
localization of VIP36 in the floating fractions, irrespectively of the glycosylation defect, can 
be observed (Fig. 3.17, line 1, 5 and 9). The same was observed for DPPIV (Fig. 3.17, line 2, 
6 and 10). The distribution of flotillin-2 and rhoA also remains the same in the CHO Lec cells 
in comparison to the control cells, still mark the DRM- and non-DRM-fractions (Fig 3.17). 
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Figure 3.17 Extraction of Tween 20 DRMs of CHO K1, Lec1, and Lec2 cells. CHO K1, Lec1, and 
Lec2 cells were lysed with Tween 20 followed by a discontinuous sucrose-density gradient. Nine 
fractions were collected from the top, ranging from 5 % sucrose in the upper fraction to 40 % sucrose 
in the lowest fraction. Western blot analysis with immunostaining of VIP36, DPPIV, flotillin-2, and 
rhoA was performed. Flotillin-2 and rhoA are controls for the DRM-fractions and the non-DRM-
fractions, respectively. 
 
To verify that VIP36 is also interacting with DPPIV in Tween 20 DRMs in the CHO K1 and 
Lec cells, immunoprecipitation with isolation of DPPIV of the first four fractions, which 
refers to the DRM-fractions, were conducted. The immunoisolates were then further 
processed by Western blotting with immunostaining of VIP36. Figure 3.18 depicts the 
interaction studies of the three cell lines. As shown for Caco-2 cells, the interaction of VIP36 
and DPPIV takes place in Tween 20 DRMs, since protein bands are detectable in these 
fractions. 
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Figure 3.18 Interaction of VIP36 with DPPIV in Tween 20 DRMs. CHO K1, Lec1, and Lec2 cells 
were lysed with Tween 20 and a discontinuous sucrose-density gradient was performed. Nine fractions 
were collected and the first four fractions, corresponding to the DRM-fractions were 
immunoprecipitated with mAb directed against DPPIV. This procedure was followed by Western blot 
analysis with immunostaining of VIP36. 
 
Extraction of Lubrol WX DRMs of the Lec cells, obtained a different band pattern of VIP36 
in comparison to the control cells. In the CHO K1 cells, VIP36 is mainly found in the non-
DRM-fractions (Fig. 3.19, line 1) as expected. It can be found in fraction 3-9. Therefore, it is 
distributed over many fractions and some VIP36 proteins are floating in the third fraction. 
However, there is a peak for this protein in fraction 7 to 9, which represents the non-DRM-
fractions as shown by the distribution of rhoA (Fig. 3.19, line 4). DPPIV can be detected in 
the DRM-fractions as well as in the non-DRM-fractions. The strongest bands can be observed 
in fraction 1 and 2, indicating that the main part of this protein is transported into Lubrol WX 
DRMs (Fig.3.19, line 2).  
In Lec1 cells, VIP36 is also distributed over many fractions (fraction 1-7) of the gradient. 
However, there are strong protein bands in the first three fractions, which represent the DRM-
fractions (Fig. 3.19, line 5). The distribution of DPPIV is comparable to that in the control 
cells, with strong protein bands in the DRM-fractions 1-3 and weaker bands in the last two 
fractions (Fig. 3.19, line 6). Flotillin-2 and rhoA show also a normal distribution (Fig. 3.19, 
line 7 and 8). 
When Lubrol WX DRMs of Lec2 cells were extracted, VIP36 is also distributed differently in 
comparison to the control cells. VIP36 can be found in fraction 1-7. Therefore, it is also 
transported in the DRM-fractions and shows a peak of protein content in fractions 3-6 (Fig. 
3.19, line 9). Again, the pattern of DPPIV did not change and is comparable to the CHO K1 
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and Lec1 cells (Fig. 3.19, line 10). The distribution of the marker proteins flotillin-2 and rhoA 
also remains unchanged in this cell line (Fig. 3.19, line 11 and 12). 
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Figure 3.19 Extraction of Lubrol WX DRMs of CHO K1, Lec1, and Lec2 cells. CHO K1, Lec1, 
and Lec2 cells were lysed with Lubrol WX followed by a discontinuous sucrose-density gradient. 
Nine fractions were collected from the top, ranging from 5 % sucrose in the upper fraction to 40 % 
sucrose in the lowest fraction. Western blot analysis with immunostaining of VIP36, DPPIV, flotillin-
2, and rhoA was performed. Flottilin-2 and rhoA are controls for the DRM-fractions and the non-
DRM-fractions, respectively. 
 
The experiment reveals that distribution of VIP36 changes in Lubrol WX DRMs when the 
glycosylation is incomplete, like in the Lec1 and Lec2 cells. This redistribution was not 
observed for the proteins DPPIV, flotillin-2 and rhoA. Therefore, VIP36 is transported into 
Lubrol WX DRMs when the glycosylation is incomplete. This suggests an interaction of 
VIP36 with its cargo at later steps of the secretory pathway when the N-glycosylation is 
incomplete and a potential role in the post-ER quality control. 
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3.10 Lipid-analysis of DRMs 
 
A defect in glycosylation, like in the CHO-Lec cells, might influence the composition of 
lipids in DRMs. To reject the hypothesis that the obtained differences in the distribution of 
VIP36 are only due to a difference in lipid composition, lipid-analysis of the different DRMs 
were conducted. 
For the lipid analysis of the three CHO cell lines, DRMs were extracted by using 1 % of 
either one of the detergents Triton X-100, Lubrol WX and Tween 20. The isolated DRM 
pellet was used for lipid extraction which was followed by TLC. Dried TLC plates (see 6.4) 
were scanned and then analyzed by the program “ImageJ 1.41i”. The quantification of the 
different lipids in µg was then calculated with “Microsoft Office Exel 2003” (see 6.5). The 
values of eight samples were used for each cell line per lipid component and DRM extraction. 
To test for significant difference between the amount of the different lipid components in µg 
for CHO K1 and the two different Lec cell lines, the Mann-Whitney U test was used. The 
working hypothesis was defined as H0: ValuesCHO = ValuesLec1 or ValuesCHO = ValuesLec2 for 
the different lipid components. The hypothesis was rejected if p-value was ≤ 0.05. 
Twelve lipid components were analyzed for the three different detergents (see 6.6). L-choline 
was not detected for any of the three cell lines when Triton X-100 DRMs were extracted, so 
that the remaining eleven lipid components were compared.  
For the extraction of Triton X-100, significant difference in lipid content was found for both 
Lec cell lines in comparison to CHO K1 cells. In the Lec1 cells, there was a significant 
increase of oleic acid (p: 0.002) and a significant decrease of ethanolamine (p: 0.038), serine 
(p: 0.038), and monoacylglycerol (p: 0.002) (Fig. 3.20). For the Lec2 cell line, a significant 
increase was also observed for oleic acid (p: 0.001) as well as a significant decrease of 
monoacylglycerol (p: 0.002) like in the Lec1 cells (Fig. 3.20). For the other lipid components, 
no significant difference was observed. 
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Figure 3.20 Analysis of Triton X-100 DRM composition. DRMs were extracted from CHO K1, 
Lec1, and Lec2 cells using the detergent Triton X-100. Lipid components were separated on TLC. 
Eight values for every cell line per detergent and lipid component were consulted for statistical 
analysis, using the Mann-Whitney U test. The figure depicts the eight values in a boxplot for the 
different cell lines and lipid components. The cross beams in every boxplot represent the median of 
the values. A star marks the significant difference of either Lec1 or Lec2 in comparison to the CHO 
K1 cell line. 0: CHO K1, 1: Lec1, 2: Lec2. 
 
When Lubrol WX DRMs were extracted, there were also differences in lipid composition for 
both Lec cell lines in comparison to CHO K1 cells. Lec1 DRM composition differs due to a 
significant increase of ethanolamine (p: 0.001) and a significant decrease of sphingomyelin 
(p: 0.003) (Fig. 3.21). Lec2 DRMs contain significant less cardiolipin (p: 0.003), cholesterol 
(p: 0.038), choline (p: 0.038), serine (p: 0.015), and sphingomyelin (p: 0.0001) (Fig. 3.21). 
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Figure 3.21 Analysis of Lubrol WX DRM composition. DRMs were extracted from CHO K1, Lec1 
and, Lec2 cells using the detergent Lubrol WX. Lipid components were separated on TLC. Eight 
values for every cell line per detergent and lipid component were consulted for statistical analysis, 
using the Mann-Whitney U test. The figure depicts the eight values in a boxplot for the different cell 
lines and lipid components. The cross beams in every boxplot represent the median of the values. A 
circle marks an outliner, defined as a value which is between 1.5 and 3 length of a box outside the box 
of all values. A star marks the significant difference of either Lec1 or Lec2 in comparison to the CHO 
K1 cell line. 0: CHO K1, 1: Lec1, 2: Lec2. 
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The extraction of Tween 20 DRMs also revealed significant differences in lipid content 
between CHO K1 and Lec1 or Lec2 cells. For Lec1 cells, a significant increase could be 
shown for ethanolamine (p: 0.010) and choline (p: 0.003) (Fig. 3.22). A significant decrease 
of galactosyl cerebroside (0.038) and monoacylglycerol (p: 0.028) was observed for the Lec2 
cell line (Fig. 3.22). 
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Figure 3.22 Analysis of Tween 20 DRM composition. DRMs were extracted from CHO K1, Lec1 
and, Lec2 cells using the detergent Tween 20. Lipid components were separated on TLC. Eight values 
for every cell line per detergent and lipid component were consulted for statistical analysis, using the 
Mann-Whitney U test. The figure depicts the eight values in a boxplot for the different cell lines and 
lipid components. The cross beams in every boxplot represent the median of the values. A star marks 
the significant difference of either Lec1 or Lec2 in comparison to the CHO K1 cell line. 0: CHO K1, 
1: Lec1, 2: Lec2.  
 
The lipid analysis showed that there are some differences in DRM composition between CHO 
K1 and the two Lec cell lines. The biggest difference could be observed for Lec1 when Triton 
X-100 extraction was performed and for Lec2 in the Lubrol WX DRMs, with four or five 
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significant alterations in the lipid content, respectively. For Tween 20 DRMs there was only a 
minor difference, only two lipid contents altered for each cell line. Since there are twelve 
lipids which were compared, the main composition of DRMs seems to be unchanged, which 
is in line with the sucrose density-gradients, where the localisation of the marker proteins 
flotillin-2 and rhoA did not change in the cell lines with glycosylation defects. Taken 
together, incomplete glycosylation has an effect on lipid composition of DRMs, but the 
DRMs itself seem to be still existent. 
 
 
3.11 Summary of the results in regard to the specific aims of the study 
 
1. By focussing on apical transmembrane glycoproteins as VIP36 interaction partners, 
the two proteins DPPIV and SI could be identified, interacting with VIP36. However, 
no interaction with the glycoproteins APN and LPH was observed. 
2. The interaction of VIP36 with the glycoproteins DPPIV and SI takes place when 
mannose-rich as well as complex glycosylated proteins are present. However, no 
interaction at the cell surface could be observed. Further, the interaction with these 
two proteins is glycosylation-dependent. When early stages of glycosylation were 
inhibited by using dNM or dMM, the binding of VIP36 to DPPIV and SI is decreased. 
The most obvious reduction of binding was found for SI when dNM treatment was 
used. A possible increase of binding could be observed for DPPIV when later steps of 
the glycosylation were inhibited, revealed in the two Lec cell lines. 
3. A DRM-association of VIP36 was found in Caco-2, CHO K1, and Lec cells by using 
the detergent Tween 20. In these microdomains, which represent DRMs of early 
compartments (e.g. ER and ERGIC), an interaction with DPPIV and SI could be 
observed. This interaction was also shown in the glycosylation-deficient Lec cell lines. 
No association with DRMs of the Golgi, extracted with Triton X-100 and Lubrol WX, 
could be shown for Caco-2 and CHO K1 cells. However, a change in the distribution 
was obtained in Lec1 and Lec2 cells, where VIP36 is associated with Lubrol WX 
DRMs. 
The lipid analysis of DRMs revealed significant differences in all three DRM-types for 
Lec1 and Lec2 cells. However, the main composition of DRMs seems to be 
unchanged, and also the localisation of the marker proteins flotillin-2 and rhoA did not 
change in the cell lines with glycosylation defects. 
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4. Discussion 
 
VIP36 is an intracellular lectin which is proposed to play a role in protein sorting and post-ER 
quality control. It was first discovered in 1994 (Fiedler et al. 1994) and isolated from MDCK 
cells, but to date its function is still not fully understood. Many studies were conducted to 
analyze sugar binding properties, cellular localization and possible cargo for this intracellular 
lectin. The aim of this study was to further characterize the function and localization of VIP36 
along the secretory pathway. Finally, I was able to identify two glycoproteins as new 
interaction partners for VIP36. Further, I could show DRM-association of this protein in 
different cellular compartments and a possible attendance of VIP36 in the early polarized 
sorting as well as in the post-ER quality control machinery. 
 
 
4.1 Intracellular localization of VIP36 
 
The cellular distribution found for VIP36 is very wide spread. It was found that this protein is 
localized mainly in the Golgi apparatus (e.g. Fiedler et al. 1994, Shimada et al. 2003b). 
Localization beyond the Golgi was found by several groups. Some showed VIP36 in 
endosomal and vesicular structures and at the basolateral and apical cell surface with 
overexpression models (Fiedler et al. 1994, Dahm et al. 2001), others identified endogenous 
VIP36 in the TGN, granules in rat parotid acinar cells, and at the apical and basolateral cell 
surface in MDCK cells (Hara-Kuge et al. 2002, Shimada et al. 2003a). However, a 
distribution in early cellular compartments was also found, identifying VIP36 in the ER and 
ERGIC (Füllekrug et al. 1999, Dahm et al. 2001). All these studies used different cell lines for 
their investigations, indicating that VIP36 localization might be cell dependent.  
In this study, it was shown that VIP36 is localized in early as well as late compartments along 
the secretory pathway. Western blot analysis revealed an appearance of VIP36 in Caco-2 and 
CHO K1 cells as well as in the glycosylation-defective cell lines Lec1 and Lec2, which were 
further used in this study. The staining of VIP36 in CHO K1 and Lec cells obtained a wide 
spread distribution of this lectin in the cell. However, no association with the cell surface was 
observed (Fig. 3.7). Pulse chase experiments using Caco-2 cells revealed that VIP36 binds to 
mannose-rich and complex glycosylated proteins, which indicate a localization of VIP36 in 
early cellular compartments like the ER and ERGIC and also in later compartments e.g. Golgi 
and TGN. 
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These data confirmed the statements made so far for VIP36 localization (Fiedler et al. 1994, 
Füllekrug et al. 1999, Hara-Kuge et al. 2002) and suggests that VIP36 might play more than 
one role in the intracellular sorting machinery due to its localization in distinct cellular 
compartments. 
 
 
4.2 VIP36 and its interaction with glycoproteins 
 
Since VIP36 is an intracellular lectin, recognizing N-linked glycans of glycoproteins, specific 
cargo or interaction partners must exist along the secretory pathway. In the past, it was found 
that VIP36 interacts with different proteins along the secretory pathway. A glycosylation-
dependent interaction of VIP36 was shown for the proteins clusterin (Hara-Kuge et al. 2002), 
α-amylase (Hara-Kuge et al. 2004), and α-1-antitrypsin (Reiterer et al. 2010), identifying 
them as cargo for VIP36. The association with the ER-resident chaperone BiP was found to 
be glycosylation independent (Nawa et al. 2007).  
BiP binds to various nascent and newly synthesized proteins in the ER, assisting their folding 
and participate in quality control processes together with CNX and CRT (Haas 1994, Kleizen 
& Braakman 2004). However, it was shown that it has in part access to post-ER 
compartments (Hammond & Helenius 1994). The binding of VIP36 was shown to be 
independent of folding processes (Nawa et al. 2007). Therefore, it is suggested that VIP36 
might interact with BiP, handing over misfolded proteins which VIP36 relocated back to the 
ER.  
The cargo identified so far for VIP36 are all soluble proteins (α-1-antitrypsin: Travis & 
Salvesen 1983, clusterin: Urban et al. 1987, α-amylase: Humphreys-Beher et al. 1982). 
Alpha-1-antitrypsin inactivates the serine proteases in blood plasma (Travis & Salvesen 
1983). Its interaction with VIP36 occurs in the early secretory pathway, when α-1-antitrypsin 
is mannose-rich glycosylated before the medial-Golgi, and this complex can be recycled back 
from the Golgi to the ER (Reiterer et al. 2010). VIP36 retards the transport of α-1-antitrypsin 
and is involved in retrograde transport, which suggests an involvement in quality control of 
VIP36 beyond the ER. 
Clusterin is released as a disulfide-linked heterodimeric complex from the apical surface of 
MDCK cells (Urban et al. 1987). It was shown that overproduction of VIP36 results into an 
increased transport of clusterin, suggesting an involvement of VIP36 in the anterograde 
transport of this protein (Hara-Kuge et al. 2002). VIP36 binds to clusterin carrying high 
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mannose-type glycans. This proposes an involvement of VIP36 in sorting events early in the 
secretory pathway. 
Alpha-amylase interacts with VIP36 in secretory vesicles in parotid gland cells (Hara-Kuge et 
al. 2004), indicating a localization later along the secretory pathway. 
Moreover, it was found that VIP36 has a higher affinity to bind membrane proteins and 
apically sorted proteins (Hara-Kuge et al. 1999, Hara-Kuge et al. 2002) and that the apical 
delivery of VIP36-recognized glycoproteins was increased due to VIP36 overexpression. 
Taken together, the studies conducted to date demonstrate a localization and lectin function in 
the early as well as in the late secretory pathway. But to date no transmembrane protein was 
identified as cargo.  
In this study, I could identify the two glycoproteins DPPIV and SI as new interaction partners 
of the mammalian L-type lectin VIP36. The two N- and O-glycosylated transmembrane 
proteins, which are apically sorted in polarized cells, are raft-associated and need this 
association for a correct targeting (reviewed in Schuck & Simons 2004). These are the first 
transmembrane glycoproteins which are defined as a possible cargo for VIP36. No binding 
activity of VIP36 could be detected for the two glycoproteins APN and LPH. These proteins 
are also apically sorted in polarized cells but their sorting is Triton X-100 raft-independent 
(Jacob & Naim 2001, Alfalah et al. 2005). It is known that raft-associated and raft-
independent proteins take distinct routes to the apical membrane (Jacob & Naim 2001, Jacob 
et al. 2003, Cresawn et al. 2007). For apical delivery they interact with different lectins (e.g. 
galectin-3 and galectin-4) in the final steps of the secretory pathway (Delacour et al. 2005, 
Delacour et al. 2006). It might be possible that there also exist two distinct lectins which 
distinguish between raft-associated and raft-independent proteins earlier in the secretory 
pathway which leads to the assumption that VIP36 is involved in the transport of apical raft-
associated proteins. An involvement in the apical sorting was already proposed by Fiedler and 
Simons in 1995 but was rejected by finding VIP36 in early cellular compartments (Füllekrug 
et al 1999). However, Hara-Kuge et al. (2002) proposed also an involvement of VIP36 in 
apical sorting events. 
Another explanation for the missing binding of VIP36 to APN could be that APN sorting is 
carbohydrate-independent (Naim et al. 1999). VIP36 might play no role for its sorting since 
there must be other mechanisms for this protein to reach its final destination. For LPH 
transport, its dimerization plays a major role, since failure leads to an ER retention followed 
by degradation (Naim & Naim 1996). VIP36 might not play a role in the sorting of LPH 
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because other proteins will initiate ER exit when it dimerizes and takes care for sorting in the 
right vesicles designated to the cell surface. 
The immunoprecipitation experiments obtained a stronger band for VIP36 when binding to 
DPPIV than to SI. However, when the expression levels of DPPIV and SI were compared, a 
much higher amount of DPPIV was found in Caco-2 cells, which is in agreement with the 
literature (Hauri et al. 1985). Therefore, the increased binding may be due to the higher 
expression level of DPPIV. 
It is also known that VIP36 binds to basolateral transported proteins (Hara-Kuge et al. 2002) 
and soluble proteins (Hara-Kuge et al. 2002, Hara-Kuge et al. 2004, Reiterer et al. 2010). 
Therefore, VIP36 might be involved in distinct transport routes along the secretory pathway 
and distinguish between apical and basolateral proteins, as well as between DRM-associated 
and DRM-independent proteins. 
 
The intracellular localization and glycosylation state of proteins, when binding to VIP36, was 
investigated, using confocal laser microscopy and pulse chase experiments. Confocal data 
obtained an association of VIP36 with DPPIV intracellularly, in vesicular structures, possibly 
in the ER and Golgi region. However, only a few colocalizations could be observed. A major 
problem in identifying cargo glycoproteins of animal lectins is their low affinity and transient 
binding (Lee & Lee 2000). This might explain the few overlapping spots in the 
immunofluorescence. The images display a steady state situation and could therefore only 
represent the binding of VIP36 to DPPIV at one time point in the cell. Since there is only a 
short time window when single VIP36 molecules interact with DPPIV or glycoproteins in 
general, it seems normal to detect only one or two interactions in a single cell. 
The pulse chase experiments revealed a binding of VIP36 to different glycoforms of 
interacting proteins. VIP36 can be found in early cellular compartments, like the ER and 
ERGIC (Füllekrug et al. 1999) which is in agreement with the data of this study. The 
interaction with DPPIV and SI was shown in the beginning of glycoprotein maturation where 
the mannose-rich form of the proteins is expressed. This support the findings of Hara-Kuge et 
al. (2002) and Reiterer et al. (2010), identifying VIP36 binding to cargo with high mannose-
type glycans in early cellular compartments. There was also binding at later stages of the 
secretory pathway shown. Binding to DPPIV occurred when the complex glycosylated form 
of this protein was present. However, in the last two chase time points there was no binding. 
At this time, DPPIV is already reaching the cell surface, showing that VIP36 releases its 
cargo in the Golgi or TGN. The same could be observed for SI, where binding was not 
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observed at the last time point. Since maturation of SI remains slower than of DPPIV (Hauri 
et al. 1985), VIP36 binds most likely at the same glycosylation stage and localization of these 
two proteins. Therefore, VIP36 might also be active as a lectin in later sorting and transport 
processes, which supports the studies of Hara-Kuge et al. (2004) and Reiterer et al. (2010).  
 
The studies conducted so far (including this one) have demonstrated that VIP36 binds only a 
restricted set of proteins, which have different tasks in the cell and function in blood plasma, 
glands or the intestine (Travis & Salvesen 1983, Humphreys-Beher et al. 1983, Matter et al. 
1990, Matter & Hauri 1991). The same was found for ERGIC-53, interacting with proteins of 
blood cells and immune cells (Nichols et al. 1998, Vollenweider et al. 1998, Appenzeller et al. 
1999, Cortini & Sitia 2010). Hara-Kuge et al. (2002) obtained, that VIP36 binds to several 
glycoproteins but the only identified cargo to date are the three proteins clusterin, α-amylase, 
and α-1-antitrypsin (Hara-Kuge et al. 2002, Hara-Kuge et al. 2004, Reiterer et al. 2010). The 
two glycoproteins DPPIV and SI are also interacting with VIP36 and this might play a role for 
its sorting. Since it is known that ERGIC-53 is acting as a cargo receptor for a limited set of 
proteins and transports them from the ER to the ERGIC, VIP36 might have the same role for 
its identified cargo in the early secretory pathway.  
 
Binding of VIP36 to DPPIV and SI was shown to be glycosylation-dependent due to the 
glycosylation-inhibitor experiments. Treatment with either dNM or dMM obtained a 
decreased binding of VIP36 to the two glycoproteins. This makes SI and DPPIV possible 
candidates for VIP36 cargo since the binding of cargo identified so far is also glycosylation-
dependent (Hara-Kuge et al. 2002, Hara-Kuge et al. 2004, Reiterer et al. 2010).  
The inhibition with dMM showed similar reductions of 39.3 % and 36.8 % for VIP36 binding 
to DPPIV and SI, respectively. DMM hampers α-mannosidase I in the cis-Golgi, preventing 
further processing of Man8GlcNAc2 glycans. It was shown that the inhibition with dMM also 
results in impaired O-glycosylation of SI and DPPIV (Naim et al. 1999). The accessibility of 
potential O-glycosylation sites to GalNAc requires a reduced number of mannose residues of 
neighbouring N-glycosylation chains (Naim et al. 1999) processed by α-mannosidase I in the 
Golgi. When O-glycosylation is hampered by steric hindrance due to dMM treatment, DPPIV 
and SI are randomly transported to the apical and basolateral cell membrane in Caco-2 cells. 
Binding could be decreased due to the hampered O-glycosylation of SI and DPPIV. The two 
proteins may be localized distinctly already at early stages in the secretory pathway when not 
sorted to the apical surface (Alfalah et al. 2005) and therefore VIP36 fails to bind to the 
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basolateral transported proteins or bind only a smaller amount as it was shown by Hara-Kuge 
et al. (2002). Normally it was expected that VIP36 binding is increased since high mannose-
type glycans are the favoured bound sugar chains (Kamiya et al. 2005). Further, the 
interaction is increased when cells were treated with kifunesine, which inhibits α-mannosidase 
I in the cis-Golgi and ER mannosidase (Reiterer et al. 2010). The binding might be disturbed 
since VIP36 could not bind to later glycoforms which were not processed due to the 
treatment. 
When the dNM treatment for the two glycoproteins was compared, it was shown that VIP36 
binding was decreased either 38.5 % or 64.7 % for DPPIV and SI, respectively. As shown in 
the pulse chase experiments, VIP36 is interacting with both glycoproteins when they are 
mannose-rich glycosylated. However, retaining of glucose on the D1-arm of the glycans 
results into a weak binding of VIP36 (Kamiya et al. 2005). Therefore, it might be possible 
that VIP36 is not able to identify and bind its cargo. Binding shortly after release from the 
CNX/CRT cycle might be more important for SI since there was a more severe reduction 
observable.  
The proposal that SI might not be correctly folded due to the treatments and therefore fails 
binding to VIP36 could be rejected by the trypsin digestion experiment. Neither the dMM 
treatment nor the dNM treatment affected SI folding, since it was cleaved by trypsin in its 
subunits sucrase and isomaltase. However, it obtained that dNM treatment did not fully work 
in the cells, not hampering the whole amount of α-glucosidase I and II. This inefficient 
treatment has also been reported by Butters et al. (1999). They reported that only 12% of total 
protein being fully endoglycosidase H-sensitive in dNM-treated CHO cells. Therefore they 
suggest the combined usage of dNM and CHO Lec3.2.8.1 cells to resolve this problem since 
these Lec cells express the same glycan processing as it is achieved with dNM treatment 
(Butters et al. 1999). However, the Lec cell model is not always suitable for investigation of 
the defined hypothesis, like in this study. Since there was only a partial inhibition of α-
glucosidase I and II it is interesting that binding of VIP36 to SI is decreased to such a great 
extent. In regard to the strong reduction of the binding it might be likely, that VIP36 cannot 
bind to SI when the N-glycosylation is hampered at a step when CNX (and CRT) are unable 
to assist SI folding. This is also in agreement with binding assays conducted by Kamiya et al. 
(2005). Since the dNM treatment only hampers part of the N-glycosylation, VIP36 might bind 
only to the SI molecules which were further bound by the lectins CNX and CRT. When the 
remaining glucose on the D1-arm is still present, VIP36 is unable to detect glycoproteins as 
cargo. The reduction suggests a main interaction of VIP36 shortly after the CNX/CRT-cycle 
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(and after binding of VIPL) as it was proposed by other studies (Kawasaki et al. 2007, 
Kamiya et al. 2008). Moreover, VIP36 binding to SI could require the previous binding of the 
mannose-rich form. As shown in the pulse chase experiment the association between SI and 
VIP36 untie before complex glycosylation is achieved. Since VIP36 cannot bind to the early 
forms of the glycosylated protein, it is likely that SI is not identified as potential cargo in later 
cellular compartments. This could result in the much weaker binding in comparison to 
DPPIV, where association is stable over the first four chase time points. 
When VIP36 does not bind to SI this glycoprotein might be missorted. The association of SI 
with Triton X-100 DRMs is important since its enzymatic activity is 3-fold higher in DRMs 
(Wetzel et al. 2009). It was shown that treatment with dMM impairs the transport of SI to 
these microdomains, reducing it’s enzymatically activity (Wetzel et al. 2009). DMM 
treatment also hampers the binding of VIP36 to SI. This suggests a function of VIP36 as a 
sorting receptor for SI routing it into the right way that it is transported into Triton X-100 
DRMs as it was found by Jacob et al. (2003). 
The results show that VIP36 require the quality control of CNX and CRT and the action of α-
glucosidase I and II to identify its cargo as interaction partners and that avoidance of protein 
maturation in the cis-Golgi results into a weaker binding. 
Inhibition of later stages of glycosylation, beyond the cis-Golgi, was examined by using Lec1 
and Lec2 cells with a defect in N-acetylglucosaminyltransferase I and CMP-sialic acid 
transporter, respectively. The immunoprecipitation revealed an increased binding of DPPIV 
by VIP36 in both cell lines. This might be a hind for VIP36 involved in post-ER quality 
control, binding to incorrect glycosylated proteins and transport them back to the ER for an 
additional round of folding or glycosylation as was shown by Reiterer et al. (2010). However, 
the expression levels of DPPIV in the Lec1 and Lec2 cells are increased in comparison to 
CHO K1 cells. Therefore, it cannot be excluded that VIP36 binds to a larger extend to DPPIV 
due to more DPPIV proteins expressed in the cell lines, as it was shown for Caco-2 cells. 
 
 
4.3 DRM-association of VIP36 
 
VIP36 was first isolated as a component of glycolipid rafts, isolated with CHAPS (Fiedler et 
al. 1994). However, later studies showed that VIP36 might not be associated with DRMs 
(Füllekrug et al. 1999). Since the cargo of VIP36 I identified in this study are two raft-
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associated proteins, I wanted to determine if there is an association with different types of 
DRMs and if they might serve as interaction platforms for VIP36 and its cargo. 
First, DRMs of Caco-2 cells were extracted using different detergents. This obtained no 
association with DRMs, extracted with Triton X-100 or Lubrol WX for VIP36. Lubrol WX 
extracts microdomains of the inner leaflet of Golgi membranes, whereas Triton X-100 DRMs 
are localized more to the outer leaflet of the Golgi and to the TGN (Delaunay et al. 2008). 
This indicates that VIP36 is not associated with DRMs which appear later along the secretory 
pathway. Since there is an interaction of VIP36 with DPPIV and SI, which are associated with 
this type of DRMs, this interaction might be DRM-independent for VIP36 and only dependent 
on N-glycosylation of cargo. 
However, a localization of VIP36 was found in DRMs which were extracted with Tween 20. 
This type of DRMs represents microdomains of the ER and ERGIC, meaning a DRM-
association of VIP36 in the early secretory pathway as was also found for DPPIV and SI 
(Alfalah et al. 2005). Alfalah et al. (2005) found, that an early polarized sorting takes place in 
Tween 20 DRMs, identifying only apical sorted proteins in these microdomains. 
Immunoprecipitation experiments revealed an interaction of VIP36 with its cargo in these 
DRMs. Therefore, it might be possible that VIP36 functions as a sorting receptor in these 
DRMs, routing apical, raft-associated proteins on their way to the apical surface. The sorting 
hypothesis of VIP36 is supported by the studies of Hara-Kuge et al. (2002), who found that 
VIP36 is interacting with more apical than basolateral sorted proteins. Further, they found that 
overexpression of VIP36 results into a more efficient apical sorting of glycoproteins, 
recognized by VIP36. A possible function of VIP36 in this purpose might be cooperation with 
galectin-4, which sorts proteins into DRMs and deliver them to the apical surface (Delaunay 
et al. 2005, Stechly et al. 2009). VIP36 might hand proteins, like DPPIV, in the TGN to 
galectin-4 for further raft-dependent apical delivery of its cargo beyond the TGN. Dependence 
of DPPIV and other raft-associated proteins on galectin-4 for reaching the apical surface was 
already shown (Stechly et al. 2009). This has to be verified also for SI. Moreover, there is 
evidence that more than one mechanism of apical sorting is existent, and that a discrimination 
of lipid raft-associated and non-associated proteins take place. This was shown for the two 
glycoproteins SI and LPH, which were routed into distinct vesicles to reach the apical surface 
(Jacob & Naim 2001, Jacob et al. 2003). Since an early polarized sorting was shown in early 
cellular compartments (Alfalah et al. 2005) it might be likely that lectins are involved in it 
like galectin-4 for raft-dependent or galectin-3 for raft-independent proteins (Delacour et al. 
2005, Delacour et al. 2006) involving VIP36 for the raft-dependent proteins. 
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Since the glycosylation plays a role for binding of VIP36 to glycoproteins the question arises 
if DRM-association was also affected. The interaction studies in the two Lec cell lines 
indicate a stronger binding of VIP36 to DPPIV when late N-glycan processing was hampered. 
The association of VIP36 with Tween 20 DRMs should not be affected since these membrane 
microdomains are present in earlier compartments, but the other two DRM-types appear in the 
Golgi where the defects are developed. By extraction of Triton X-100 and Tween 20 DRMs 
of the two Lec cell lines, I couldn`t observe any difference in the distribution of VIP36, 
DPPIV or the marker proteins flotillin-2 and rhoA. Therefore, it could be shown for these two 
extractions that inhibition of N-glycosylation beyond the cis-Golgi does not disturb the 
association with DRMs, and the DRM integrity remains intact referred to the distribution of 
marker proteins.  
The DRM extraction with Lubrol WX reveals that VIP36 is usually not found in these 
microdomains as shown for Caco-2 and CHO K1 cells. However, in both Lec cell lines VIP36 
can be found more in the DRM fractions of the sucrose-density gradient. Delaunay et al. 
(2008) found that Lubrol WX DRMs represent more the inner leaflet of the Golgi membrane, 
indicating that VIP36 is located on this side of the membrane in this cellular compartment. 
This binding might also explain the stronger bands in the Western blot experiments after 
immunoprecipitation of DPPIV.  
It might be likely that VIP36 is recruited into these microdomains because of an incomplete 
glycosylation either of itself, or of its cargo. Since this redistribution was not found in Triton 
X-100 DRMs under the same conditions it can be excluded that the glycosylation of VIP36 
plays a role. Moreover, it was shown that VIP36 showing normal localization and binding 
properties when its N-glycosylation side was removed (Reiterer et al. 2010). 
It is questionable why VIP36 is recruited into these specific microdomains. One possible 
explanation could be that VIP36 might interact more with DPPIV when glycosylation is 
incorrect and is therefore recruited due to the interaction with DPPIV, since not all VIP36 was 
found exclusively in the DRM fractions of the gradient. The hypothesis that redistribution 
might be due to a change in lipid composition was also followed up. The TLC experiments 
revealed differences in some of the lipid components in Lec1 and Lec2 cells for all the 
extractions. However, no clear model for increase or decrease of special components for the 
different detergents and cell lines was observed. In addition, the major part of the investigated 
components showed no significant change for the two cell lines and different extractions, 
indicating DRM integrity in Lec1 and Lec2 cell membranes. For Lubrol WX DRMs a 
decrease in cholesterol for Lec2 cells and sphingomyelin for Lec1 and Lec2 cells was 
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observed, which are the main components of DRMs or lipid rafts (Simons & Ikonen 1997, 
Brown & London 1998). This might be the most severe change in lipid composition, which 
could result into a redistribution of DRMs. However, it was shown that complete depletion of 
DRM components e.g. sphingolipids or cholesterol do not affect lipid raft integrity 
(Ostermeyer et al. 1999, Klappe et al. 2010). Moreover, the marker proteins for DRM- and 
non-DRM-fractions in the sucrose-density gradient still mark the expected fractions. 
Therefore, it is likely that changes in distribution of VIP36 in Lubrol WX DRMs are not due 
to the changes in the lipid composition but to the incomplete N-glycosylation of its cargo in 
the Golgi.  
It is suggested that VIP36 might play an important role in post-ER quality control (Reiterer et 
al. 2010). The observed redistribution might also be a hind for quality control of VIP36 
binding to DPPIV and possibly transport it back to earlier compartments for an additional 
round of glycosylation. Post-ER quality control is mentioned a lot in the literature, since it 
was found that some misfolded or incomplete glycosylated proteins escape the ER and are 
further transported through the secretory pathway (VanSlyke et al. 2000, Ashok & Hegde 
2009, Reiterer et al. 2010). This was also found for DPPIV in Lec cells. To date, the 
mechanisms behind and the involved proteins of post-ER quality control are poorly 
understood and only some proteins are suggested to play a role in this mechanism. Some of 
these proteins which are involved in retrieval mechanisms to the ER are known to be 
localized in the ERGIC (e.g. KDEL receptor: Yamamoto et al. 2001), others can be found in 
the Golgi (Vps10p: Jorgensen et al. 1999, Rab6: White et al. 1999, Tul1p (for membrane 
proteins): Reggiori & Pelham 2002, Wsc1p: Wang & Ng 2010). Since a retrograde transport 
was found for VIP36 together with its cargo (Füllekrug et al. 1999, Reiterer et al. 2010), it is 
likely that VIP36 is involved in this step of the sorting machinery, also indicated by the 
glycosylation-independent interaction with the chaperone BiP which was also shown in 
retrograde vesicles directed to the ER and also in the ER (Nawa et al. 2007).  
 
 
4.4 Lectin function of VIP36 in the secretory pathway 
 
My data, in combination with known features of VIP36 leads to the following model (Fig. 
4.1) for the interaction with glycoproteins like DPPIV and SI: 
VIP36 binds to correctly folded proteins directly after the CNX/CRT cycle and binding of 
VIPL in the ER. Here, it functions as a cargo receptor for a set of glycoproteins, in the same 
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manner as the lectin ERGIC-53. It traffics with its cargo to the ERGIC, where binding is still 
existent. In the ERGIC it is associated with Tween 20 DRMs and is involved in the apical 
sorting machinery, possibly for raft-dependent proteins like DPPIV and SI. After this step, 
VIP36 transports its cargo to the Golgi. In the Golgi, the interaction with cargo might separate 
temporarily as shown for SI or remains also in this compartment. When VIP36 binds to 
glycoproteins in the medial- and trans-Golgi it scans them for their proper glycosylation. If 
the interacting glycoprotein is not correctly glycosylated, it is recycled back by VIP36 to 
earlier compartments for an additional round of glycan processing. For this step it might be 
recruited into DRMs of the inner leaflet of the Golgi. Finally, in the TGN VIP36 might hand 
terminal glycosylated proteins to other lectins, like galectin-4 for raft-associated proteins, 
which then transport them to their final destination, e.g. the apical cell surface for DPPIV and 
SI. 
In conclusion, my data showed that VIP36 may exert its functions at different sites of the 
secretory pathway. 
 
 
Figure 4.1 VIP36 and its interaction with glycoproteins along the secretory pathway. VIP36 
binds to high-mannose type glycans on glycoproteins in the ER after the action of CNX/CRT and 
VIPL. It traffics with cargo to the ERGIC, like ERGIC-53. In the ERGIC, VIP36 is associated with 
Tween 20 DRMs and is possibly involved in early polarized sorting for apical proteins. The lectin-
glycoprotein complex travels to the Golgi. Here, VIP36 scans its cargo for correct glycosylation, not 
associated with DRMs. When proteins are not correctly glycosylated, VIP36 might relocated them 
back to earlier compartments (e.g. ER) and is possibly recruited into Lubrol WX DRMs. Terminal 
glycosylated proteins are released in the TGN and possibly handed to other lectins e.g. galectin-4 for 
raft-associated proteins. G: glucose, M: mannose, N: GlcNAc, Ga: galactose, SA: sialic acid, Gal-4: 
galectin-4, underlined VIP36: DRM-associated. 
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4.5 Concluding remarks and outlook 
 
In this study, it could be shown that VIP36 is interacting with the transmembrane 
glycoproteins DPPIV and SI in a glycosylation-dependent manner. These two proteins are 
raft-associated, which is crucial for their proper sorting and trafficking. Since no interaction 
with raft-independent proteins could be shown in this study, VIP36 might play a role in the 
sorting of raft-dependent proteins. It was found that VIP36 recognize and bind to DPPIV and 
SI in their mannose-rich and complex glycosylated form. This indicates an interaction in the 
ER and ERGIC as well as in the Golgi and TGN. No interaction could be observed at the cell 
surface and also pulse chase experiments showed no binding of VIP36 to the two 
glycoproteins when they supposed to reach the cell surface. Therefore, VIP36 might play a 
role in early sorting events and release the proteins in the TGN, where it might hand its cargo 
to other lectins like galectin-4 for raft-associated proteins (e.g. DPPIV). The inhibition of 
early steps of glycosylation obtained a decreased binding for VIP36 to its cargo. Therefore, 
VIP36 might require the previous quality control of the lectins CNX and CRT. The inhibiton 
of glycosylation beyond the cis-Golgi showed a possible increase in binding of VIP36 to 
DPPIV and SI, suggesting a binding to incomplete glycosylated proteins for retrograde 
transport to earlier compartments and with this involvement in post-ER quality control. 
An association of VIP36 with DRMs along the secretoy pathway was also shown in this 
study. VIP36 was isolated from Tween 20 DRMs, which represent sorting platforms for 
apical trafficking. Therefore, it might play a role in early polarized sorting of raft-associated 
proteins, since an interaction with DPPIV and SI in these DRMs could be shown. No 
association of VIP36 with DRMs of the Golgi, extracted with Lubrol WX or Triton X-100, 
could be observed. This suggests that the interaction with glycoproteins is only glycosylation 
dependent later along the secretory pathway. When the glycosylation was inhibited beyond 
the cis-Golgi, VIP36 could be found in Lubrol WX DRMs. However, DRM integrity seems to 
be intact. This suggests recruitment of VIP36 into these microdomains, binding to incorrect 
glycosylated proteins for a retrograde transport and post-ER quality control.  
 
Taken together, in this work more information about VIP36 was obtained, supporting its 
involvement in early sorting, apical sorting and post-ER quality control. Although it seems 
hard-to-believe that one protein can have so many functions in the cell; I think that my data 
together with the studies conducted so far are a good hind that VIP36 is a multifunctional 
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intracellular lectin. However, more studies are necessary to define the processes in which 
VIP36 is involved. 
Since the absence of CNX and CRT in mice caused lethality (reviewed in Anelli & Sitia 
2008) and mutation in ERGIC-53 bleeding disorder (Nichols et al. 1998) it would be 
interesting to generate a VIP36 knockout cell line or mouse model to investigate the effects 
on protein sorting and apical delivery of proteins. Knockdown of VIP36 was conducted by 
Reiterer et al. (2010) in HepG2 cells. They found a difference in trafficking of α-1-antitrypsin, 
showing an increasing transport. It would be interesting to investigate DPPIV and SI in a 
VIP36 knockout Caco-2 cell line. With this it could be determine if VIP36 directly influences 
apical targeting of DPPIV and SI or not. Further, the interaction with other lectins at later 
steps of the secretory pathway should be investigated to determine if VIP36 might hand its 
cargo to other lectins which transport them to the cell surface.  
The study gave an additional insight into sorting events along the secretory pathway. Such 
studies are important to learn more about the complicated sorting machinery which can be 
found in cells and with this to enhance our understanding of cellular processes which are 
influenced or altered by certain pathomechanisms. 
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6.4 TCL-plates of lipid analysis 
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6.5 Lipid content of DRM-fractions of CHO K1, Lec1, and Lec2 cells.  
 
DRMs were isolated from CHO K1, Lec1 and, Lec2 cells with the detergents Triton X 100 (TX 100), 
Lubrol WX (Lubrol), and Tween 20 (K1: CHO K1, L1: Lec1, L2: Lec2). 
Lipid component µg cell line   µg cell line   µg Cell line 
Cholesterol ester 241,213 K1 Tx 100   100,191 K1 Lubrol   90,464 K1 Tween 20 
Cholesterol ester 240,837 K1 Tx 100   99,378 K1 Lubrol   102,510 K1 Tween 20 
Cholesterol ester 243,854 K1 Tx 100   103,662 K1 Lubrol   89,325 K1 Tween 20 
Cholesterol ester 243,342 K1 Tx 100   102,239 K1 Lubrol   90,316 K1 Tween 20 
Cholesterol ester 243,051 K1 Tx 100   231,438 K1 Lubrol   124,961 K1 Tween 20 
Cholesterol ester 239,290 K1 Tx 100   190,939 K1 Lubrol   113,901 K1 Tween 20 
Cholesterol ester 249,910 K1 Tx 100   233,847 K1 Lubrol   106,759 K1 Tween 20 
Cholesterol ester 246,355 K1 Tx 100   219,980 K1 Lubrol   109,623 K1 Tween 20 
Cholesterol ester 295,895 L1 Tx 100   123,191 L1 Lubrol   92,991 L1 Tween 20  
Cholesterol ester 298,837 L1 Tx 100   111,186 L1 Lubrol   89,052 L1 Tween 20 
Cholesterol ester 330,605 L1 Tx 100   114,908 L1 Lubrol   95,229 L1 Tween 20 
Cholesterol ester 342,773 L1 Tx 100   122,060 L1 Lubrol   94,715 L1 Tween 20 
Cholesterol ester 199,947 L1 Tx 100   274,482 L1 Lubrol   123,861 L1 Tween 20 
Cholesterol ester 236,825 L1 Tx 100   269,999 L1 Lubrol   125,393 L1 Tween 20 
Cholesterol ester 123,063 L1 Tx 100   103,348 L1 Lubrol   245,426 L1 Tween 20 
Cholesterol ester 121,275 L1 Tx 100   103,070 L1 Lubrol   210,837 L1 Tween 20 
Cholesterol ester 295,333 L2 Tx 100   121,641 L2 Lubrol   79,771 L2 Tween 20 
Cholesterol ester 297,758 L2 Tx 100   119,369 L2 Lubrol   81,541 L2 Tween 20 
Cholesterol ester 300,646 L2 Tx 100   117,245 L2 Lubrol   101,145 L2 Tween 20 
Cholesterol ester 297,663 L2 Tx 100   116,114 L2 Lubrol   96,414 L2 Tween 20 
Cholesterol ester 127,445 L2 Tx 100   77,119 L2 Lubrol   222,654 L2 Tween 20 
Cholesterol ester 128,496 L2 Tx 100   86,786 L2 Lubrol   212,537 L2 Tween 20 
Cholesterol ester 143,623 L2 Tx 100   96,886 L2 Lubrol   98,386 L2 Tween 20 
Cholesterol ester 144,267 L2 Tx 100   90,378 L2 Lubrol   108,662 L2 Tween 20 
                  
Triglycerides 120,394 K1 Tx 100   110,847 K1 Lubrol   105,767 K1 Tween 20 
Triglycerides 116,124 K1 Tx 100   109,103 K1 Lubrol   118,007 K1 Tween 20 
Triglycerides 122,888 K1 Tx 100   104,440 K1 Lubrol   101,201 K1 Tween 20 
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Triglycerides 124,812 K1 Tx 100   105,930 K1 Lubrol   105,011 K1 Tween 20 
Triglycerides 124,731 K1 Tx 100   143,862 K1 Lubrol   209,425 K1 Tween 20 
Triglycerides 125,959 K1 Tx 100   146,362 K1 Lubrol   209,378 K1 Tween 20 
Triglycerides 129,920 K1 Tx 100   163,115 K1 Lubrol   188,633 K1 Tween 20 
Triglycerides 137,641 K1 Tx 100   161,056 K1 Lubrol   184,774 K1 Tween 20 
Triglycerides 156,742 L1 Tx 100   101,222 L1 Lubrol   107,043 L1 Tween 20 
Triglycerides 154,671 L1 Tx 100   102,811 L1 Lubrol   105,040 L1 Tween 20 
Triglycerides 0,000 L1 Tx 100   102,288 L1 Lubrol   119,616 L1 Tween 20 
Triglycerides 0,000 L1 Tx 100   104,276 L1 Lubrol   111,857 L1 Tween 20 
Triglycerides 186,375 L1 Tx 100   155,305 L1 Lubrol   201,169 L1 Tween 20 
Triglycerides 207,686 L1 Tx 100   157,364 L1 Lubrol   203,335 L1 Tween 20 
Triglycerides 166,444 L1 Tx 100   203,496 L1 Lubrol   132,196 L1 Tween 20 
Triglycerides 165,025 L1 Tx 100   203,103 L1 Lubrol   134,466 L1 Tween 20 
Triglycerides 0,000 L2 Tx 100   108,708 L2 Lubrol   93,145 L2 Tween 20 
Triglycerides 0,000 L2 Tx 100   106,154 L2 Lubrol   93,418 L2 Tween 20 
Triglycerides 0,000 L2 Tx 100   105,099 L2 Lubrol   109,054 L2 Tween 20 
Triglycerides 0,000 L2 Tx 100   105,414 L2 Lubrol   110,484 L2 Tween 20 
Triglycerides 201,150 L2 Tx 100   129,523 L2 Lubrol   126,893 L2 Tween 20 
Triglycerides 201,453 L2 Tx 100   130,209 L2 Lubrol   128,826 L2 Tween 20 
Triglycerides 171,500 L2 Tx 100   134,614 L2 Lubrol   137,287 L2 Tween 20 
Triglycerides 170,847 L2 Tx 100   133,151 L2 Lubrol   144,567 L2 Tween 20 
                  
Oleic acid 74,789 K1 Tx 100   126,658 K1 Lubrol   82,136 K1 Tween 20 
Oleic acid 77,115 K1 Tx 100   111,015 K1 Lubrol   92,539 K1 Tween 20 
Oleic acid 91,982 K1 Tx 100   111,894 K1 Lubrol   73,889 K1 Tween 20 
Oleic acid 91,270 K1 Tx 100   117,048 K1 Lubrol   77,961 K1 Tween 20 
Oleic acid 87,893 K1 Tx 100   110,085 K1 Lubrol   217,304 K1 Tween 20 
Oleic acid 89,675 K1 Tx 100   122,361 K1 Lubrol   209,434 K1 Tween 20 
Oleic acid 105,638 K1 Tx 100   122,111 K1 Lubrol   201,696 K1 Tween 20 
Oleic acid 108,204 K1 Tx 100   122,313 K1 Lubrol   199,341 K1 Tween 20 
Oleic acid 102,481 L1 Tx 100   105,596 L1 Lubrol   100,893 L1 Tween 20 
Oleic acid 102,520 L1 Tx 100   111,535 L1 Lubrol   105,638 L1 Tween 20 
Oleic acid 113,153 L1 Tx 100   97,909 L1 Lubrol   114,989 L1 Tween 20 
Oleic acid 118,330 L1 Tx 100   100,465 L1 Lubrol   102,648 L1 Tween 20 
Oleic acid 111,275 L1 Tx 100   111,796 L1 Lubrol   250,103 L1 Tween 20 
Oleic acid 118,825 L1 Tx 100   111,783 L1 Lubrol   248,664 L1 Tween 20 
Oleic acid 136,346 L1 Tx 100   241,158 L1 Lubrol   115,549 L1 Tween 20 
Oleic acid 136,973 L1 Tx 100   245,743 L1 Lubrol   117,392 L1 Tween 20 
Oleic acid 105,633 L2 Tx 100   113,088 L2 Lubrol   80,767 L2 Tween 20 
Oleic acid 106,784 L2 Tx 100   114,462 L2 Lubrol   79,682 L2 Tween 20 
Oleic acid 110,098 L2 Tx 100   109,302 L2 Lubrol   123,518 L2 Tween 20 
Oleic acid 112,067 L2 Tx 100   113,510 L2 Lubrol   114,661 L2 Tween 20 
Oleic acid 228,253 L2 Tx 100   107,680 L2 Lubrol   116,798 L2 Tween 20 
Oleic acid 228,488 L2 Tx 100   103,652 L2 Lubrol   118,683 L2 Tween 20 
Oleic acid 156,786 L2 Tx 100   118,278 L2 Lubrol   109,829 L2 Tween 20 
Oleic acid 155,439 L2 Tx 100   114,256 L2 Lubrol   115,801 L2 Tween 20 
                  
Cholesterol 86,655 K1 Tx 100   226,310 K1 Lubrol   88,854 K1 Tween 20 
Cholesterol 86,201 K1 Tx 100   230,899 K1 Lubrol   247,745 K1 Tween 20 
Cholesterol 222,503 K1 Tx 100   198,973 K1 Lubrol   62,894 K1 Tween 20 
Cholesterol 226,110 K1 Tx 100   196,329 K1 Lubrol   62,966 K1 Tween 20 
Cholesterol 204,291 K1 Tx 100   187,986 K1 Lubrol   206,307 K1 Tween 20 
Cholesterol 203,822 K1 Tx 100   192,244 K1 Lubrol   219,873 K1 Tween 20 
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Cholesterol 176,169 K1 Tx 100   188,381 K1 Lubrol   215,836 K1 Tween 20 
Cholesterol 178,715 K1 Tx 100   187,087 K1 Lubrol   219,118 K1 Tween 20 
Cholesterol 156,140 L1 Tx 100   211,696 L1 Lubrol   157,472 L1 Tween 20 
Cholesterol 161,169 L1 Tx 100   223,662 L1 Lubrol   159,725 L1 Tween 20 
Cholesterol 152,134 L1 Tx 100   227,452 L1 Lubrol   171,362 L1 Tween 20 
Cholesterol 153,436 L1 Tx 100   252,004 L1 Lubrol   173,003 L1 Tween 20 
Cholesterol 155,901 L1 Tx 100   182,225 L1 Lubrol   256,731 L1 Tween 20 
Cholesterol 181,755 L1 Tx 100   186,078 L1 Lubrol   273,923 L1 Tween 20 
Cholesterol 170,664 L1 Tx 100   223,158 L1 Lubrol   186,064 L1 Tween 20 
Cholesterol 173,416 L1 Tx 100   228,179 L1 Lubrol   195,335 L1 Tween 20 
Cholesterol 188,057 L2 Tx 100   203,129 L2 Lubrol   72,078 L2 Tween 20 
Cholesterol 190,566 L2 Tx 100   201,103 L2 Lubrol   76,271 L2 Tween 20 
Cholesterol 170,827 L2 Tx 100   176,201 L2 Lubrol   165,723 L2 Tween 20 
Cholesterol 174,017 L2 Tx 100   171,020 L2 Lubrol   163,140 L2 Tween 20 
Cholesterol 264,694 L2 Tx 100   168,780 L2 Lubrol   173,615 L2 Tween 20 
Cholesterol 255,725 L2 Tx 100   164,613 L2 Lubrol   172,658 L2 Tween 20 
Cholesterol 200,067 L2 Tx 100   160,507 L2 Lubrol   147,756 L2 Tween 20 
Cholesterol 203,318 L2 Tx 100   165,486 L2 Lubrol   156,543 L2 Tween 20 
                  
Monoacylglycerol 70,791 K1 Tx 100   100,204 K1 Lubrol   80,572 K1 Tween 20 
Monoacylglycerol 75,343 K1 Tx 100   99,506 K1 Lubrol   110,857 K1 Tween 20 
Monoacylglycerol 103,846 K1 Tx 100   91,881 K1 Lubrol   73,829 K1 Tween 20 
Monoacylglycerol 110,754 K1 Tx 100   91,222 K1 Lubrol   77,819 K1 Tween 20 
Monoacylglycerol 97,884 K1 Tx 100   80,274 K1 Lubrol   102,871 K1 Tween 20 
Monoacylglycerol 95,525 K1 Tx 100   83,985 K1 Lubrol   101,776 K1 Tween 20 
Monoacylglycerol 100,593 K1 Tx 100   80,055 K1 Lubrol   110,617 K1 Tween 20 
Monoacylglycerol 100,160 K1 Tx 100   82,598 K1 Lubrol   110,544 K1 Tween 20 
Monoacylglycerol 0,000 L1 Tx 100   74,872 L1 Lubrol   80,191 L1 Tween 20 
Monoacylglycerol 0,000 L1 Tx 100   80,982 L1 Lubrol   87,489 L1 Tween 20 
Monoacylglycerol 0,000 L1 Tx 100   92,356 L1 Lubrol   89,966 L1 Tween 20 
Monoacylglycerol 0,000 L1 Tx 100   93,826 L1 Lubrol   91,466 L1 Tween 20 
Monoacylglycerol 0,000 L1 Tx 100   0,000 L1 Lubrol   93,268 L1 Tween 20 
Monoacylglycerol 0,000 L1 Tx 100   0,000 L1 Lubrol   101,251 L1 Tween 20 
Monoacylglycerol 86,428 L1 Tx 100   73,472 L1 Lubrol   72,931 L1 Tween 20 
Monoacylglycerol 81,985 L1 Tx 100   80,742 L1 Lubrol   77,850 L1 Tween 20 
Monoacylglycerol 0,000 L2 Tx 100   100,473 L2 Lubrol   84,151 L2 Tween 20 
Monoacylglycerol 0,000 L2 Tx 100   99,021 L2 Lubrol   79,837 L2 Tween 20 
Monoacylglycerol 0,000 L2 Tx 100   96,823 L2 Lubrol   95,431 L2 Tween 20 
Monoacylglycerol 0,000 L2 Tx 100   94,316 L2 Lubrol   87,840 L2 Tween 20 
Monoacylglycerol 93,899 L2 Tx 100   66,001 L2 Lubrol   68,448 L2 Tween 20 
Monoacylglycerol 84,153 L2 Tx 100   64,032 L2 Lubrol   67,052 L2 Tween 20 
Monoacylglycerol 0,000 L2 Tx 100   57,849 L2 Lubrol   68,590 L2 Tween 20 
Monoacylglycerol 0,000 L2 Tx 100   57,841 L2 Lubrol   69,499 L2 Tween 20 
                  
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   117,797 K1 Tween 20 
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   110,433 K1 Tween 20 
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   104,568 K1 Tween 20 
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   106,794 K1 Tween 20 
Galactosyl cerebroside  0,000 K1 Tx 100   0,000 K1 Lubrol   114,867 K1 Tween 20 
Galactosyl cerebroside  0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
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Galactosyl cerebroside  0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
Galactosyl cerebroside  0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
Galactosyl cerebroside  0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
Galactosyl cerebroside  0,000 L1 Tx 100   0,000 L1 Lubrol   99,922 L1 Tween 20 
Galactosyl cerebroside  0,000 L1 Tx 100   0,000 L1 Lubrol   112,476 L1 Tween 20 
Galactosyl cerebroside  0,000 L1 Tx 100   88,689 L1 Lubrol   0,000 L1 Tween 20 
Galactosyl cerebroside  0,000 L1 Tx 100   98,982 L1 Lubrol   0,000 L1 Tween 20 
Galactosyl cerebroside  0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
Galactosyl cerebroside  0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
Galactosyl cerebroside  0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
Galactosyl cerebroside 0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
Galactosyl cerebroside  135,773 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
Galactosyl cerebroside  124,963 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
Galactosyl cerebroside  0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
Galactosyl cerebroside  0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
                  
Ethanolamine 0,000 K1 Tx 100   328,843 K1 Lubrol   0,000 K1 Tween 20 
Ethanolamine 0,000 K1 Tx 100   347,687 K1 Lubrol   231,949 K1 Tween 20 
Ethanolamine 150,327 K1 Tx 100   318,393 K1 Lubrol   0,000 K1 Tween 20 
Ethanolamine 162,451 K1 Tx 100   313,037 K1 Lubrol   0,000 K1 Tween 20 
Ethanolamine 145,550 K1 Tx 100   281,305 K1 Lubrol   192,391 K1 Tween 20 
Ethanolamine 141,359 K1 Tx 100   317,746 K1 Lubrol   196,586 K1 Tween 20 
Ethanolamine 277,219 K1 Tx 100   293,975 K1 Lubrol   169,849 K1 Tween 20 
Ethanolamine 257,731 K1 Tx 100   303,023 K1 Lubrol   168,166 K1 Tween 20 
Ethanolamine 92,686 L1 Tx 100   340,600 L1 Lubrol   335,124 L1 Tween 20 
Ethanolamine 103,090 L1 Tx 100   410,792 L1 Lubrol   344,100 L1 Tween 20 
Ethanolamine 104,079 L1 Tx 100   407,485 L1 Lubrol   380,947 L1 Tween 20 
Ethanolamine 106,542 L1 Tx 100   488,588 L1 Lubrol   382,743 L1 Tween 20 
Ethanolamine 0,000 L1 Tx 100   410,848 L1 Lubrol   144,737 L1 Tween 20 
Ethanolamine 0,000 L1 Tx 100   422,385 L1 Lubrol   194,397 L1 Tween 20 
Ethanolamine 0,000 L1 Tx 100   335,835 L1 Lubrol   226,582 L1 Tween 20 
Ethanolamine 0,000 L1 Tx 100   382,623 L1 Lubrol   234,382 L1 Tween 20 
Ethanolamine 153,352 L2 Tx 100   401,212 L2 Lubrol   0,000 L2 Tween 20 
Ethanolamine 149,406 L2 Tx 100   388,534 L2 Lubrol   0,000 L2 Tween 20 
Ethanolamine 130,396 L2 Tx 100   309,340 L2 Lubrol   352,152 L2 Tween 20 
Ethanolamine 142,176 L2 Tx 100   325,340 L2 Lubrol   333,578 L2 Tween 20 
Ethanolamine 96,817 L2 Tx 100   307,605 L2 Lubrol   171,531 L2 Tween 20 
Ethanolamine 98,123 L2 Tx 100   322,131 L2 Lubrol   161,261 L2 Tween 20 
Ethanolamine 95,120 L2 Tx 100   206,807 L2 Lubrol   103,584 L2 Tween 20 
Ethanolamine 103,159 L2 Tx 100   211,777 L2 Lubrol   114,749 L2 Tween 20 
                  
Cardiolipin 0,000 K1 Tx 100   78,010 K1 Lubrol   0,000 K1 Tween 20 
Cardiolipin 0,000 K1 Tx 100   83,996 K1 Lubrol   45,894 K1 Tween 20 
Cardiolipin 39,489 K1 Tx 100   72,295 K1 Lubrol   0,000 K1 Tween 20 
Cardiolipin 40,847 K1 Tx 100   76,079 K1 Lubrol   0,000 K1 Tween 20 
Cardiolipin 37,106 K1 Tx 100   62,251 K1 Lubrol   37,149 K1 Tween 20 
Cardiolipin 36,700 K1 Tx 100   70,847 K1 Lubrol   42,450 K1 Tween 20 
Cardiolipin 40,862 K1 Tx 100   65,502 K1 Lubrol   41,624 K1 Tween 20 
Cardiolipin 41,600 K1 Tx 100   66,735 K1 Lubrol   42,961 K1 Tween 20 
Cardiolipin 30,181 L1 Tx 100   52,852 L1 Lubrol   111,362 L1 Tween 20 
Cardiolipin 37,258 L1 Tx 100   69,968 L1 Lubrol   114,716 L1 Tween 20 
Cardiolipin 32,640 L1 Tx 100   77,945 L1 Lubrol   124,814 L1 Tween 20 
Cardiolipin 33,613 L1 Tx 100   93,505 L1 Lubrol   124,881 L1 Tween 20 
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Cardiolipin 0,000 L1 Tx 100   69,871 L1 Lubrol   30,292 L1 Tween 20 
Cardiolipin 0,000 L1 Tx 100   75,072 L1 Lubrol   35,524 L1 Tween 20 
Cardiolipin 0,000 L1 Tx 100   60,936 L1 Lubrol   31,461 L1 Tween 20 
Cardiolipin 0,000 L1 Tx 100   68,127 L1 Lubrol   32,042 L1 Tween 20 
Cardiolipin 34,122 L2 Tx 100   68,354 L2 Lubrol   0,000 L2 Tween 20 
Cardiolipin 32,922 L2 Tx 100   65,723 L2 Lubrol   0,000 L2 Tween 20 
Cardiolipin 35,144 L2 Tx 100   53,546 L2 Lubrol   117,888 L2 Tween 20 
Cardiolipin 37,559 L2 Tx 100   60,239 L2 Lubrol   121,418 L2 Tween 20 
Cardiolipin 38,778 L2 Tx 100   58,940 L2 Lubrol   35,560 L2 Tween 20 
Cardiolipin 37,993 L2 Tx 100   61,346 L2 Lubrol   31,581 L2 Tween 20 
Cardiolipin 39,966 L2 Tx 100   40,448 L2 Lubrol   30,797 L2 Tween 20 
Cardiolipin 41,800 L2 Tx 100   42,005 L2 Lubrol   34,466 L2 Tween 20 
                  
Serine 0,000 K1 Tx 100   172,012 K1 Lubrol   0,000 K1 Tween 20 
Serine 0,000 K1 Tx 100   186,117 K1 Lubrol   81,194 K1 Tween 20 
Serine 63,268 K1 Tx 100   152,382 K1 Lubrol   0,000 K1 Tween 20 
Serine 65,096 K1 Tx 100   157,062 K1 Lubrol   0,000 K1 Tween 20 
Serine 59,408 K1 Tx 100   112,638 K1 Lubrol   77,215 K1 Tween 20 
Serine 60,961 K1 Tx 100   127,294 K1 Lubrol   78,391 K1 Tween 20 
Serine 77,234 K1 Tx 100   119,109 K1 Lubrol   75,243 K1 Tween 20 
Serine 79,380 K1 Tx 100   118,261 K1 Lubrol   75,326 K1 Tween 20 
Serine 43,779 L1 Tx 100   91,550 L1 Lubrol   94,718 L1 Tween 20 
Serine 47,643 L1 Tx 100   120,852 L1 Lubrol   96,137 L1 Tween 20 
Serine 46,497 L1 Tx 100   132,212 L1 Lubrol   106,907 L1 Tween 20 
Serine 47,668 L1 Tx 100   175,045 L1 Lubrol   106,681 L1 Tween 20 
Serine 0,000 L1 Tx 100   118,418 L1 Lubrol   55,966 L1 Tween 20 
Serine 0,000 L1 Tx 100   121,211 L1 Lubrol  74,120 L1 Tween 20 
Serine 0,000 L1 Tx 100   96,504 L1 Lubrol   68,380 L1 Tween 20 
Serine 0,000 L1 Tx 100   105,651 L1 Lubrol   72,095 L1 Tween 20 
Serine 48,574 L2 Tx 100   134,066 L2 Lubrol   0,000 L2 Tween 20 
Serine 50,166 L2 Tx 100   135,746 L2 Lubrol   0,000 L2 Tween 20 
Serine 50,966 L2 Tx 100   109,284 L2 Lubrol   100,451 L2 Tween 20 
Serine 56,611 L2 Tx 100   117,078 L2 Lubrol   103,888 L2 Tween 20 
Serine 50,907 L2 Tx 100   93,727 L2 Lubrol   66,925 L2 Tween 20 
Serine 52,787 L2 Tx 100   94,324 L2 Lubrol   60,824 L2 Tween 20 
Serine 55,335 L2 Tx 100   62,934 L2 Lubrol   54,610 L2 Tween 20 
Serine 62,811 L2 Tx 100   67,560 L2 Lubrol   58,845 L2 Tween 20 
                  
Choline  29,299 K1 Tx 100   165,135 K1 Lubrol   29,629 K1 Tween 20 
Choline  31,454 K1 Tx 100   165,628 K1 Lubrol   138,345 K1 Tween 20 
Choline  79,925 K1 Tx 100   162,709 K1 Lubrol   27,240 K1 Tween 20 
Choline  83,315 K1 Tx 100   170,872 K1 Lubrol   28,460 K1 Tween 20 
Choline  79,021 K1 Tx 100   122,117 K1 Lubrol   129,524 K1 Tween 20 
Choline  75,899 K1 Tx 100   138,001 K1 Lubrol   130,144 K1 Tween 20 
Choline  145,532 K1 Tx 100   128,268 K1 Lubrol   128,748 K1 Tween 20 
Choline  149,664 K1 Tx 100   127,596 K1 Lubrol   125,848 K1 Tween 20 
Choline  63,111 L1 Tx 100   134,093 L1 Lubrol   187,126 L1 Tween 20 
Choline  66,936 L1 Tx 100   158,419 L1 Lubrol   191,830 L1 Tween 20 
Choline  60,059 L1 Tx 100   163,488 L1 Lubrol   209,660 L1 Tween 20 
Choline  60,618 L1 Tx 100   189,874 L1 Lubrol   206,551 L1 Tween 20 
Choline  34,136 L1 Tx 100   150,146 L1 Lubrol   119,661 L1 Tween 20 
Choline  38,319 L1 Tx 100   153,694 L1 Lubrol   163,461 L1 Tween 20 
Choline  36,876 L1 Tx 100   115,999 L1 Lubrol   157,336 L1 Tween 20 
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Choline  36,525 L1 Tx 100   131,107 L1 Lubrol   161,701 L1 Tween 20 
Choline  87,876 L2 Tx 100   150,824 L2 Lubrol   0,000 L2 Tween 20 
Choline  88,814 L2 Tx 100   149,106 L2 Lubrol   0,000 L2 Tween 20 
Choline  80,009 L2 Tx 100   126,567 L2 Lubrol   188,432 L2 Tween 20 
Choline  83,953 L2 Tx 100   129,445 L2 Lubrol   177,420 L2 Tween 20 
Choline  86,320 L2 Tx 100   111,630 L2 Lubrol   123,085 L2 Tween 20 
Choline  82,046 L2 Tx 100   115,935 L2 Lubrol   122,499 L2 Tween 20 
Choline  84,424 L2 Tx 100   79,122 L2 Lubrol   84,617 L2 Tween 20 
Choline  81,941 L2 Tx 100   83,036 L2 Lubrol   88,777 L2 Tween 20 
                  
Sphingomyelin 22,796 K1 Tx 100   144,624 K1 Lubrol   21,867 K1 Tween 20 
Sphingomyelin 24,332 K1 Tx 100   155,203 K1 Lubrol   161,053 K1 Tween 20 
Sphingomyelin 113,584 K1 Tx 100   127,162 K1 Lubrol   0,000 K1 Tween 20 
Sphingomyelin 125,748 K1 Tx 100   137,888 K1 Lubrol   0,000 K1 Tween 20 
Sphingomyelin 108,431 K1 Tx 100   108,911 K1 Lubrol   71,521 K1 Tween 20 
Sphingomyelin 77,339 K1 Tx 100   121,056 K1 Lubrol   72,829 K1 Tween 20 
Sphingomyelin 144,904 K1 Tx 100   113,357 K1 Lubrol   72,635 K1 Tween 20 
Sphingomyelin 148,204 K1 Tx 100   116,274 K1 Lubrol   69,768 K1 Tween 20 
Sphingomyelin 65,975 L1 Tx 100   92,170 L1 Lubrol   78,707 L1 Tween 20 
Sphingomyelin 68,907 L1 Tx 100   113,203 L1 Lubrol   80,442 L1 Tween 20 
Sphingomyelin 61,547 L1 Tx 100   105,041 L1 Lubrol   94,865 L1 Tween 20 
Sphingomyelin 65,214 L1 Tx 100   123,694 L1 Lubrol   93,006 L1 Tween 20 
Sphingomyelin 28,485 L1 Tx 100   101,623 L1 Lubrol   52,053 L1 Tween 20 
Sphingomyelin 37,878 L1 Tx 100   102,105 L1 Lubrol   77,210 L1 Tween 20 
Sphingomyelin 29,349 L1 Tx 100   80,535 L1 Lubrol   69,811 L1 Tween 20 
Sphingomyelin 30,088 L1 Tx 100   90,565 L1 Lubrol   74,271 L1 Tween 20 
Sphingomyelin 107,687 L2 Tx 100   91,108 L2 Lubrol   0,000 L2 Tween 20 
Sphingomyelin 108,734 L2 Tx 100   89,115 L2 Lubrol   0,000 L2 Tween 20 
Sphingomyelin 87,050 L2 Tx 100   72,445 L2 Lubrol   82,351 L2 Tween 20 
Sphingomyelin 94,106 L2 Tx 100   80,723 L2 Lubrol   78,527 L2 Tween 20 
Sphingomyelin 102,929 L2 Tx 100   86,059 L2 Lubrol   55,368 L2 Tween 20 
Sphingomyelin 95,924 L2 Tx 100   92,450 L2 Lubrol   60,025 L2 Tween 20 
Sphingomyelin 88,451 L2 Tx 100   64,128 L2 Lubrol   42,979 L2 Tween 20 
Sphingomyelin 90,237 L2 Tx 100   66,283 L2 Lubrol   45,527 L2 Tween 20 
                  
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 K1 Tx 100   0,000 K1 Lubrol   0,000 K1 Tween 20 
L-Choline 0,000 L1 Tx 100   51,725 L1 Lubrol   58,765 L1 Tween 20 
L-Choline 0,000 L1 Tx 100   56,598 L1 Lubrol   62,021 L1 Tween 20 
L-Choline 0,000 L1 Tx 100   72,819 L1 Lubrol   83,200 L1 Tween 20 
L-Choline 0,000 L1 Tx 100   48,650 L1 Lubrol   75,488 L1 Tween 20 
L-Choline 0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
L-Choline 0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
L-Choline 0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
L-Choline 0,000 L1 Tx 100   0,000 L1 Lubrol   0,000 L1 Tween 20 
L-Choline 0,000 L2 Tx 100   60,444 L2 Lubrol   0,000 L2 Tween 20 
L-Choline 0,000 L2 Tx 100   57,537 L2 Lubrol   0,000 L2 Tween 20 
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L-Choline 0,000 L2 Tx 100   57,782 L2 Lubrol   73,833 L2 Tween 20 
L-Choline 0,000 L2 Tx 100   58,826 L2 Lubrol   74,877 L2 Tween 20 
L-Choline 0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
L-Choline 0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
L-Choline 0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
L-Choline 0,000 L2 Tx 100   0,000 L2 Lubrol   0,000 L2 Tween 20 
 
 
6.6 Results of the Mann-Whitney U test 
 
For the analysis of lipid components the Mann-Whitney U test was used. It was tested for 
significant differences in the amount of lipid components between CHO K1 (0) and Lec1 (1) 
or between CHO K1 (0) and Lec2 (2). The tables show the data conducted by using the 
program SPSS (version 18, PSAW). 
 
For Triton X-100 extraction: 
Cholesterol ester: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,50 60,00 
1 8 9,50 76,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,75 70,00 
2 8 8,25 66,00 
microgram 
Gesamt 16   
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 24,000 
Wilcoxon-W 60,000 
Z -,840 
Asymptotische 
Signifikanz (2-seitig) 
,401 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,442
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 30,000 
Wilcoxon-W 66,000 
Z -,210 
Asymptotische 
Signifikanz (2-seitig) 
,834 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,878
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
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Triglycerides: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 6,50 52,00 
1 8 10,50 84,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,50 68,00 
2 8 8,50 68,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Oleic acid: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 5,00 40,00 
1 8 12,00 96,00 
Microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -1,682 
Asymptotische 
Signifikanz (2-seitig) 
,093 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 32,000 
Wilcoxon-W 68,000 
Z ,000 
Asymptotische 
Signifikanz (2-seitig) 
1,000 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
1,000
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 4,000 
Wilcoxon-W 40,000 
Z -2,941 
Asymptotische 
Signifikanz (2-seitig) 
,003 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,002
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
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Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 4,88 39,00 
2 8 12,13 97,00 
Microgram 
Gesamt 16   
 
 
 
 
 
Cholesterol: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,25 82,00 
1 8 6,75 54,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,00 64,00 
2 8 9,00 72,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 3,000 
Wilcoxon-W 39,000 
Z -3,046 
Asymptotische 
Signifikanz (2-seitig) 
,002 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,001
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 18,000 
Wilcoxon-W 54,000 
Z -1,470 
Asymptotische 
Signifikanz (2-seitig) 
,141 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,161
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 28,000 
Wilcoxon-W 64,000 
Z -,420 
Asymptotische 
Signifikanz (2-seitig) 
,674 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,721
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
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Monoacylglycerol: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 12,00 96,00 
1 8 5,00 40,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 12,00 96,00 
2 8 5,00 40,00 
microgram 
Gesamt 16   
 
 
 
 
 
Galactosyl cerebroside: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,50 68,00 
1 8 8,50 68,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 4,000 
Wilcoxon-W 40,000 
Z -3,019 
Asymptotische 
Signifikanz (2-seitig) 
,003 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,002
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 4,000 
Wilcoxon-W 40,000 
Z -3,019 
Asymptotische 
Signifikanz (2-seitig) 
,003 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,002
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 32,000 
Wilcoxon-W 68,000 
Z ,000 
Asymptotische 
Signifikanz (2-seitig) 
1,000 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
1,000
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
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Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,50 60,00 
2 8 9,50 76,00 
microgram 
Gesamt 16   
 
 
 
 
 
Ethanolamine: 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,00 88,00 
1 8 6,00 48,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,75 78,00 
2 8 7,25 58,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 24,000 
Wilcoxon-W 60,000 
Z -1,461 
Asymptotische 
Signifikanz (2-seitig) 
,144 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,442
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 12,000 
Wilcoxon-W 48,000 
Z -2,157 
Asymptotische 
Signifikanz (2-seitig) 
,031 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,038
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 22,000 
Wilcoxon-W 58,000 
Z -1,051 
Asymptotische 
Signifikanz (2-seitig) 
,293 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,328
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
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Cardiolipin: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,75 86,00 
1 8 6,25 50,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,63 69,00 
2 8 8,38 67,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Serine: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,00 88,00 
1 8 6,00 48,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 14,000 
Wilcoxon-W 50,000 
Z -1,941 
Asymptotische 
Signifikanz (2-seitig) 
,052 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,065
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 31,000 
Wilcoxon-W 67,000 
Z -,105 
Asymptotische 
Signifikanz (2-seitig) 
,916 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,959
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 12,000 
Wilcoxon-W 48,000 
Z -2,157 
Asymptotische 
Signifikanz (2-seitig) 
,031 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,038
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
130 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,25 82,00 
2 8 6,75 54,00 
microgram 
Gesamt 16   
 
 
 
 
 
Choline: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,50 84,00 
1 8 6,50 52,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 6,88 55,00 
2 8 10,13 81,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 18,000 
Wilcoxon-W 54,000 
Z -1,471 
Asymptotische 
Signifikanz (2-seitig) 
,141 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,161
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -1,680 
Asymptotische 
Signifikanz (2-seitig) 
,093 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 19,000 
Wilcoxon-W 55,000 
Z -1,365 
Asymptotische 
Signifikanz (2-seitig) 
,172 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,195
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Sphingomyelin: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,50 84,00 
1 8 6,50 52,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,38 75,00 
2 8 7,63 61,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
L-choline: 
Ränge 
 cell line N Mittlerer Rang Rangsumme 
0 8 8,50 68,00 
1 8 8,50 68,00 
Microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -1,680 
Asymptotische 
Signifikanz (2-seitig) 
,093 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 25,000 
Wilcoxon-W 61,000 
Z -,735 
Asymptotische 
Signifikanz (2-seitig) 
,462 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,505
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 32,000 
Wilcoxon-W 68,000 
Z ,000 
Asymptotische 
Signifikanz (2-seitig) 
1,000 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
1,000
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,50 68,00 
2 8 8,50 68,00 
Microgram 
Gesamt 16   
 
 
 
 
 
 
For Lubrol WX extraction: 
Cholesterol ester: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,75 62,00 
1 8 9,25 74,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,50 84,00 
2 8 6,50 52,00 
microgram 
Gesamt 16   
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 32,000 
Wilcoxon-W 68,000 
Z ,000 
Asymptotische 
Signifikanz (2-seitig) 
1,000 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
1,000
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 26,000 
Wilcoxon-W 62,000 
Z -,630 
Asymptotische 
Signifikanz (2-seitig) 
,529 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,574
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -1,680 
Asymptotische 
Signifikanz (2-seitig) 
,093 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Triglycerides: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,00 72,00 
1 8 8,00 64,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,75 78,00 
2 8 7,25 58,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Oleic acid: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,75 78,00 
1 8 7,25 58,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 28,000 
Wilcoxon-W 64,000 
Z -,420 
Asymptotische 
Signifikanz (2-seitig) 
,674 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,721
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 22,000 
Wilcoxon-W 58,000 
Z -1,050 
Asymptotische 
Signifikanz (2-seitig) 
,294 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,328
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 22,000 
Wilcoxon-W 58,000 
Z -1,050 
Asymptotische 
Signifikanz (2-seitig) 
,294 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,328
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,50 84,00 
2 8 6,50 52,00 
microgram 
Gesamt 16   
 
 
 
 
 
Cholesterol: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,50 60,00 
1 8 9,50 76,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,00 88,00 
2 8 6,00 48,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -1,680 
Asymptotische 
Signifikanz (2-seitig) 
,093 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 24,000 
Wilcoxon-W 60,000 
Z -,840 
Asymptotische 
Signifikanz (2-seitig) 
,401 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,442
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 12,000 
Wilcoxon-W 48,000 
Z -2,100 
Asymptotische 
Signifikanz (2-seitig) 
,036 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,038
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Monoacylglycerol: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,50 84,00 
1 8 6,50 52,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,25 74,00 
2 8 7,75 62,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Galactosyl cerebroside: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,50 60,00 
1 8 9,50 76,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -1,682 
Asymptotische 
Signifikanz (2-seitig) 
,093 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 26,000 
Wilcoxon-W 62,000 
Z -,630 
Asymptotische 
Signifikanz (2-seitig) 
,529 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,574
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 24,000 
Wilcoxon-W 60,000 
Z -1,461 
Asymptotische 
Signifikanz (2-seitig) 
,144 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,442
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
136 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,50 68,00 
2 8 8,50 68,00 
microgram 
Gesamt 16   
 
 
 
 
 
Ethanolamine: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 4,75 38,00 
1 8 12,25 98,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,25 66,00 
2 8 8,75 70,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 32,000 
Wilcoxon-W 68,000 
Z ,000 
Asymptotische 
Signifikanz (2-seitig) 
1,000 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
1,000
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 2,000 
Wilcoxon-W 38,000 
Z -3,151 
Asymptotische 
Signifikanz (2-seitig) 
,002 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,001
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 30,000 
Wilcoxon-W 66,000 
Z -,210 
Asymptotische 
Signifikanz (2-seitig) 
,834 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,878
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
137 
Cardiolipin: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,00 72,00 
1 8 8,00 64,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,88 95,00 
2 8 5,13 41,00 
microgram 
Gesamt 16   
 
 
 
 
 
Serine: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,13 81,00 
1 8 6,88 55,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 28,000 
Wilcoxon-W 64,000 
Z -,420 
Asymptotische 
Signifikanz (2-seitig) 
,674 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,721
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 5,000 
Wilcoxon-W 41,000 
Z -2,836 
Asymptotische 
Signifikanz (2-seitig) 
,005 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,003
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 19,000 
Wilcoxon-W 55,000 
Z -1,365 
Asymptotische 
Signifikanz (2-seitig) 
,172 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,195
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
138 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,38 91,00 
2 8 5,63 45,00 
microgram 
Gesamt 16   
 
 
 
 
 
Choline: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,63 69,00 
1 8 8,38 67,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,00 88,00 
2 8 6,00 48,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 9,000 
Wilcoxon-W 45,000 
Z -2,415 
Asymptotische 
Signifikanz (2-seitig) 
,016 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,015
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 31,000 
Wilcoxon-W 67,000 
Z -,105 
Asymptotische 
Signifikanz (2-seitig) 
,916 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,959
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 12,000 
Wilcoxon-W 48,000 
Z -2,100 
Asymptotische 
Signifikanz (2-seitig) 
,036 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,038
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Sphingomyelin: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,88 95,00 
1 8 5,13 41,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 12,50 100,00 
2 8 4,50 36,00 
microgram 
Gesamt 16   
 
 
 
 
 
L-Choline: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 6,50 52,00 
1 8 10,50 84,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 5,000 
Wilcoxon-W 41,000 
Z -2,836 
Asymptotische 
Signifikanz (2-seitig) 
,005 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,003
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U ,000 
Wilcoxon-W 36,000 
Z -3,361 
Asymptotische 
Signifikanz (2-seitig) 
,001 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,000
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -2,208 
Asymptotische 
Signifikanz (2-seitig) 
,027 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
140 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 6,50 52,00 
2 8 10,50 84,00 
microgram 
Gesamt 16   
 
 
 
 
 
For Tween 20 extraction: 
 
Cholesterol ester: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,50 60,00 
1 8 9,50 76,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,75 70,00 
2 8 8,25 66,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -2,208 
Asymptotische 
Signifikanz (2-seitig) 
,027 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 24,000 
Wilcoxon-W 60,000 
Z -,840 
Asymptotische 
Signifikanz (2-seitig) 
,401 
Exakte Signifikanz [2*(1-
seitig Sig.)] 
,442
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 30,000 
Wilcoxon-W 66,000 
Z -,210 
Asymptotische 
Signifikanz (2-seitig) 
,834 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,878
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Triglycerides: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,50 68,00 
1 8 8,50 68,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,75 78,00 
2 8 7,25 58,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Oleic acid: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,50 60,00 
1 8 9,50 76,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 32,000 
Wilcoxon-W 68,000 
Z ,000 
Asymptotische 
Signifikanz (2-seitig) 
1,000 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
1,000
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 22,000 
Wilcoxon-W 58,000 
Z -1,050 
Asymptotische 
Signifikanz (2-seitig) 
,294 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,328
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 24,000 
Wilcoxon-W 60,000 
Z -,840 
Asymptotische 
Signifikanz (2-seitig) 
,401 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,442
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,00 72,00 
2 8 8,00 64,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Cholesterol: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,25 66,00 
1 8 8,75 70,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,75 78,00 
2 8 7,25 58,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 28,000 
Wilcoxon-W 64,000 
Z -,420 
Asymptotische 
Signifikanz (2-seitig) 
,674 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,721
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 30,000 
Wilcoxon-W 66,000 
Z -,210 
Asymptotische 
Signifikanz (2-seitig) 
,834 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,878
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 22,000 
Wilcoxon-W 58,000 
Z -1,050 
Asymptotische 
Signifikanz (2-seitig) 
,294 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,328
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
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Monoacylglycerol: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,13 81,00 
1 8 6,88 55,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,13 89,00 
2 8 5,88 47,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Galactosyl cerebroside: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 10,25 82,00 
1 8 6,75 54,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 19,000 
Wilcoxon-W 55,000 
Z -1,365 
Asymptotische 
Signifikanz (2-seitig) 
,172 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,195
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 11,000 
Wilcoxon-W 47,000 
Z -2,205 
Asymptotische 
Signifikanz (2-seitig) 
,027 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,028
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 18,000 
Wilcoxon-W 54,000 
Z -1,620 
Asymptotische 
Signifikanz (2-seitig) 
,105 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,161
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
144 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 11,00 88,00 
2 8 6,00 48,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Ethanolamine: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 5,50 44,00 
1 8 11,50 92,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,38 67,00 
2 8 8,63 69,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 12,000 
Wilcoxon-W 48,000 
Z -2,554 
Asymptotische 
Signifikanz (2-seitig) 
,011 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,038
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 8,000 
Wilcoxon-W 44,000 
Z -2,528 
Asymptotische 
Signifikanz (2-seitig) 
,011 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,010
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 31,000 
Wilcoxon-W 67,000 
Z -,107 
Asymptotische 
Signifikanz (2-seitig) 
,915 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,959
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
145 
Cardiolipin: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,00 56,00 
1 8 10,00 80,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,63 69,00 
2 8 8,38 67,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Serine: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,00 56,00 
1 8 10,00 80,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 20,000 
Wilcoxon-W 56,000 
Z -1,264 
Asymptotische 
Signifikanz (2-seitig) 
,206 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,234
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 31,000 
Wilcoxon-W 67,000 
Z -,107 
Asymptotische 
Signifikanz (2-seitig) 
,915 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,959
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 20,000 
Wilcoxon-W 56,000 
Z -1,264 
Asymptotische 
Signifikanz (2-seitig) 
,206 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,234
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
146 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 8,63 69,00 
2 8 8,38 67,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
Choline: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 5,13 41,00 
1 8 11,88 95,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,00 72,00 
2 8 8,00 64,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 31,000 
Wilcoxon-W 67,000 
Z -,107 
Asymptotische 
Signifikanz (2-seitig) 
,915 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,959
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 5,000 
Wilcoxon-W 41,000 
Z -2,836 
Asymptotische 
Signifikanz (2-seitig) 
,005 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,003
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 28,000 
Wilcoxon-W 64,000 
Z -,420 
Asymptotische 
Signifikanz (2-seitig) 
,674 
Exakte Signifikanz [2*(1-
seitig Sig.)] 
,721
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
147 
Sphingomyelin: 
Ränge 
 Cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 6,38 51,00 
1 8 10,63 85,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 9,00 72,00 
2 8 8,00 64,00 
microgram 
Gesamt 16   
 
 
 
 
 
L-Choline: 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 6,50 52,00 
1 8 10,50 84,00 
microgram 
Gesamt 16   
 
 
 
 
 
 
 
 
 
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 15,000 
Wilcoxon-W 51,000 
Z -1,787 
Asymptotische 
Signifikanz (2-seitig) 
,074 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,083
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 28,000 
Wilcoxon-W 64,000 
Z -,423 
Asymptotische 
Signifikanz (2-seitig) 
,672 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,721
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 16,000 
Wilcoxon-W 52,000 
Z -2,208 
Asymptotische 
Signifikanz (2-seitig) 
,027 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,105
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
APPENDIX 
148 
Ränge 
 cell line 
N 
Mittlerer 
Rang Rangsumme 
0 8 7,50 60,00 
2 8 9,50 76,00 
microgram 
Gesamt 16   
 
 
Statistik für Test
b
 
 microgram 
Mann-Whitney-U 24,000 
Wilcoxon-W 60,000 
Z -1,461 
Asymptotische 
Signifikanz (2-seitig) 
,144 
Exakte Signifikanz 
[2*(1-seitig Sig.)] 
,442
a
 
a. Nicht für Bindungen korrigiert. 
b. Gruppenvariable: cell line 
